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1. Summary 
The past years have seen an enormous scientific interest in the field of DNA methylation. Numerous 
studies have documented the functional significance of DNA methylation in the regulation of gene 
expression and the maintenance of local chromatin structure. A large body of evidence underlines the 
implication of aberrant DNA methylation in nearly all types of human cancers. 
The focus of the current work was to investigate the role of DNA methylation in the human immune 
system at candidate immune-relevant genes by emphasising two key biological aspects.  
First, the role of DNA methylation as an epigenetic mark, possessing the function to memorize the 
expression phenotype, was analyzed within key cytokine genes. Large-scale methylation profiling 
experiments of these genes were carried out in designated CD4+ memory T-cells subsets. DNA 
methylation in the IL10 gene, encoding the anti-inflammatory cytokine IL-10 and in the IFNγ  gene, 
encoding the pro-inflammatory cytokine IFN-γ were of special interest due to the key role of these 
molecules in the immune response. 
Cell type specific differentially methylated regions were found in the genes encoding the cytokines IL-
13 and IL-4 in DNA sequences that were previously shown to harbor regulatory elements. This finding 
suggests a role for DNA methylation in the expression regulation of these genes. 
As for the gene encoding the cytokine IFN-γ, low levels of DNA-methylation were measured in human 
ex vivo IFN-γ expressing cells at several CpGs located proximal to the transcription start site and within 
an enhancer element 5.0 kb upstream. At the same time, IFN-γ non-expressing cells were shown to be 
strongly upmethylated at the same CpG sites. The specific role of this methylation pattern as a 
heritable epigenetic mark for rapid expression induction was demonstrated through experiments 
carried out in vitro. Further in vitro cultivation experiments were performed to investigate the dynamics 
between site-specific demethylation and expression induction in the IFNγ gene. 
In contrast, DNA methylation does not seem to play any role in the regulation of the IL10 gene. With 
the exception of two CpGs located in the proximal promoter, slightly demethylated in IL-10 producing 
cells, no differential methylation was measured between IL-10 expressing and non-expressing cells. 
The two questionable CpGs do not harbour the epigenetic memory mark for expression since in vitro 
cultivation of IL-10+ cells under expansive conditions rapidly results in the loss of IL-10 expression 
without measurable methylation changes at these sites. Further epigenetic analysis at the level of 
histones revealed covalent modifications like hyperacetylation and trimethylation that are associated 
with an open chromatin status in IL-10 producing cells as compared to their non-expressing 
counterparts. These findings led to the conclusion, that the IL10 gene is excluded from the functional 
cytokine memory in human Th cells, preventing the generation of memory cells with an inherited 
program to secrete IL-10, possibly to ensure a limited effect of IL-10 in downregulation of adaptive 
pathogen-specific immunity. 
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As a second biological aspect, variations in the level of DNA methylation during development and 
maturization of the B- and T-cell lineage were monitored in key transcription factors. A set of cell types, 
resembling major steps of the human hematopoietic development were employed for this analysis. 
It could be shown that variations in the local methylation of several transcription factor genes (SPI1, 
TCF7, c-maf, Etv5, TBX21 and GATA3) is an accompanying feature during development and lineage 
maturation. For some genes (SPI1, Eomes and Etv5), an inverse correlation between promoter 
methylation and the respective gene expression could be demonstrated, suggesting an implication for 
DNA methylation in the expression of these genes. 
Some of the hereby-discovered regions of differential methylation between individual cell types were 
tested for their use in diagnostic applications such as rheumatoid arthritis, endometriosis and 
lymphoma. 
Specific differentially methylated CpGs in the IFNγ gene were successfully used to measure balance 
shifts of T-helper cell compartments in the peripheral blood of patients with rheumatoid arthritis. By 
means of the same marker, no differential methylation was found in the endometrium of women with 
endometriosis as compared to non-endometriosis controls. 
Methylation information from specific factors (SPI1, TCF7, c-maf and eomes) was applied to show 
aberrant methylation patterns in a B-cell malignancy of the lymph node when compared to healthy 
tissue. Thus, transcription factors may represent a novel class of aberrantly methylated genes in 
hematopoietic cancer. In addition, the used candidate gene approach is a valid one for identifying 
novel tumor biomarkers. 
.
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2. Introduction 
2.1. Role of DNA methylation in the mammalian organism 
2.1.1. DNA methylation in humans: patterns and functions 
In contrast to classical genetics investigating the inheritance and changes of the genetic code, 
epigenetics refers to all mechanisms that are not encoded within the genomic sequence and confer to 
specialized cells a particular and heritable spectrum of gene expression (1), (2). Three key epigenetic 
mechanisms are described as being responsible for the propagation of the gene transcription and 
repression information (3): histone modifications like histone alkylation, RNA associated gene 
repression and DNA methylation (4). 
The most stable epigenetic modification of mammalian DNA is the methylation at the 5’ position of 
cytosines found almost exclusively in the context of 5’–cytosine guanine–3’ (CG) dinucleotides (5), (6). 
The occurrence of CpG dinucleotides in the human genome is only 5–10% of the statistically predicted 
frequency (7). This underrepresentation is likely due to the high mutation frequency of methylated 
cytosines as they undergo spontaneous deamination and are thereby converted to thymine. The result 
is a point mutation at the respective site. Series of spontaneous deamination in the course of evolution 
are thought to be the cause of CpG duplets depletion in the genome. 
The non-random distribution of CG dinucleotides in the genome is of great functional significance. 
When scanning the genomic sequence for CG dinucleotide pairs, regions with higher proportions of CG 
dinucleotides than would be expected by chance, are found. These regions are referred to as CpG 
islands (CGI) and constitute between 1% and 2% of the total genome. The vast majority of CGIs are 
unmethylated (8), (9) although this finding depends to some extent on the specific definition of a CGI. 
At present, the widely accepted CGI definition proposed by Gardiner and Frommer requires a 
sequence length of at least 500bp with a GC content of at least 55% and a ratio between observed and 
expected CpG dinucleotides of 0.65 (10). The majority of CGIs are located within gene promoters while 
non-CGI containing promoters tend to be depleted in CpGs (11). Promoter CGIs are frequently, but not 
exclusively, associated with housekeeping genes and are usually, but not always, methylation free. 
Several CGIs are located within genes that have a tissue restricted expression pattern. CpGs outside 
of CpG islands, with 70% to 80% of the total genomic CpG duplets, are largely methylated (12) and are 
typical of the densely packed, transcriptionally inactive chromatin. Among them are repetitive elements, 
transposons, and the inactivated X – chromosome. 
CpG methylation is maintained by a series of DNA methyltransferases (DNMTs) with different 
functionalities. Most de novo methylation events occur at early embryonic stages, following the drastic, 
genome wide methylation decrease observed after fertilization. They are induced by the Dnmt3A and 
Dnmt3B, two de novo methyltransferases which are highly expressed at this stage (13).  
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However, the pattern after which de novo DNA methylation is positioned in the genome in the early 
phase of embryonic development is still elusive. It has been suggested, that de novo methylation in the 
early embryo is induced preferentially at genomic regions with silent chromatin contributing to the 
stabilisation of the silencing (6). Simultaneously, transcriptionally active promoters at early embryonic 
stages remain unmethylated leading thus to the unmethylated CpG islands found in the adult somatic 
tissue (14). 
The maintenance of an aquired methylation pattern during somatic cell division is thought to follow a 
semiconservative mechanism: the methylation information is copied from the parental strand to the 
daughter strand by the Dnmt1 (15). This methyltransferase was shown to have a high affinity for 
hemimethylated substrates as they occur after DNA replication. 
The mechanisms underlying the reverse process of DNA demethylation have not yet been elucidated. 
In principle, it can be achieved passively after abolishing maintenance methylation in the course of cell 
division. Two classes of enzymes may account for an active demethylation process: DNA 
demethylases and DNA glycosylases. Although the removal of the CH3 group by breaking the covalent 
carbon bound is energetically unfavourable, evidence of DNA demethylase activity is provided in vitro 
for both hemimethylated and fully methylated dsDNA substrates (16). The activity of a DNA 
glycosylase removing the methylated cytosine from a m5CpG pair when methylation is present on both 
strands has been described as the first of a two step process followed by the replacement of the 
excised base through DNA repair enzymes (17) (18). 
DNA methylation accounts for several effects in healthy tissue. An increase in methylation results in 
stable transcriptional silencing as evidenced in the X chromosomal inactivation, genomic imprinting, the 
stabilisation of chromosomes by silencing of transposable elements (19), (20), and the regulation of 
tissue restricted gene expression. Further, DNA methylation plays a crucial role during embryonic 
development (21). In the following paragraphs, some examples of known DNA methylation effects are 
highlighted. 
 
X chromosome inactivation 
X-inactivation in females is a process by which one of the two copies of X-chromosome present in 
female mammals is inactivated. The choice of which X chromosome will be inactivated is random but 
once an X chromosome is inactivated, it will remain inactive throughout the lifetime of the cell.  
In contrast to the active X the inactive X chromosome (Barr body) has high levels of DNA methylation, 
low levels of histone acetylation, low levels of histone H3 lysine-4 methylation, and high levels of 
histone H3 lysine-9 methylation. Each of these epigenetic marks is associated with heterochromatin 
formation and gene silencing and mediates the inactivation of the chromosome. The X-inactivation 
center (XIC), a region on the X- chromosome encodes for two non-translated mRNAs: the Xist and the 
Tsix mRNA, transcribed antisense to Xist. Xist RNA accumulates along the X chromosome containing 
the active XIST gene and proceeds to inactivate almost all of the other hundreds of genes on that 
chromosome. Following this physical deactivation, large parts of the chromosome are silenced by DNA 
methylation. The Xist gene on the active X chromosome is silenced by DNA methylation (22). 
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Tsix mRNA is a negative regulator of Xist: it acts by preventing its abundant accumulation on the active 
X chromosome (23). 
 
Genomic imprinting 
DNA methylation plays a crucial role in genomic imprinting, a phenomenon in mammals where the 
father and mother contribute different epigenetic patterns for specific genomic loci in their germ cells 
resulting in an allele-specific gene expression for some genes. 
Imprinting is mostly achieved through DNA hypermethylation at one of the two parental alleles of a 
gene. This is already affectuated in the gamete or the zygote with the consequence of monoallelic 
expression of the gene (24). Differential expression can occur in all cells, or in specific tissues or 
developmental stages. About 80 genes are currently known to be imprinted, and this number is 
continually increasing. Prominent non – cancerous imprinting disorders are the Beckwith-Wiedemann, 
the Prader–Willi and the Rett syndrome (25). 
Conversely, loss of imprinting (LOI) is the disruption of imprinted epigenetic marks through gain or loss 
of DNA methylation, or simply the loss of normal allele-specific gene expression (26). LOI deserves 
special attention since it is a frequent event in tumor development. There, acquired defects in the 
imprinting of e.g. growth-promoting genes lead to activation of the normally silent allele and result in 
abnormally high expression of the gene product. Consequently, the cell gains a growth advantage. A 
prominent example of such aberrant activation is the insulin growth factor 2 gene IGF2 / H19 locus 
mapping to 11p15.5 where defective imprinting of the IGF2 gene is the most common LOI event across 
a wide range of tumor types, including colon, liver, lung, and ovarian cancer, as well as Wilms’ tumor 
(27), (28). 
 
Silencing of repetitive elements 
Cytosine methylation inactivates the promoters of most viruses and transposable elements, including 
retroviruses and Alu elements. Thus, unconstrained transposition possibly leading to chromosome 
instability and large expression of irrelevant promoters is efficiently blocked (29), (30), (31). 
Hypomethylation, defined as the decreased level of DNA methylation at a certain genomic region, is 
frequently seen in the promoters of the parasitic elements in cancer cells as a consequence of global 
hypomethylation. The methylation dependent reactivation of these elements is a driving force towards 
the genetic instability seen in cancer cells (32).  
 
Tissue specific methylation 
An increasing number of genes are described as being methylated in a tissue specific manner. Often, 
the methylation pattern can be correlated to their expression status in the respective tissue. In addition, 
recent studies, including the work presented here, have revealed several tissue specific methylation 
patterns outside of gene and proximal promoter regions and of yet unknown functionality (33), (34). 
A large number of examples are available demonstrating that CpG islands contain tissue-dependent 
and differentially methylated regions (T-DMR) which are potential methylation sites in normal cells and 
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tissues. It was hypothesised that during tissue differentiation and development, transcriptionally 
relevant regions in the genome become selectively de- or upmethylated to enable the transcription of a 
restricted set of genes within a given tissue. This can occur during both, embryonic tissue 
differentiation and adult stem cell differentiation (hematopoiesis, bone marrow stem cell differentiation) 
(35), (36). Prominent examples are the germline specific genes like the melanoma antigen gene family 
MAGE (MAGE-A1 and LAGE-1) encoding tumor specific antigens. The promoters of these genes 
consist of CGIs which are essentially unmethylated in germline cells but become strongly methylated in 
somatic tissue (37). Song et al. have identified T-DMRs in the mouse located in the 5’ regions of 
transcription factor genes and demonstrated the inverse correlation between methylation and 
expression for several tissues (brain, kidney, liver, testis, colon and muscle) (38). Further, large scale 
methylation studies involving entire chromosomes have revealed several T-DMR loci and correlated 
their methylation patterns with transcription in several tissues (39), (33). 
Weber et al. have recently demonstrated that especially weak CpG island promoters, with a relatively 
low level of CpGs, are predisposed to de novo DNA methylation during development and that these 
types of promoters are most frequent in tissue specific expressed genes (14). 
 
DNA methylation in embryonic development 
Experiments in mice have demonstrated radical changes in the genome – wide methylation level 
during gametogenesis, fertilisation and early embryo formation. 
During gametogenesis, a genome – wide DNA methylation erasure process followed by a re-
methylation, has been described (40). After fertilisation, the genomes inherited from both sperm and 
oocytes undergo another cycle of erasure of most of their associated DNA methylation. While the 
paternal genome is actively demethylated, the methylation on the maternal genome is removed 
passively during cell division processes. It is not before the gastrulation (implantation) of the zygote 
and the differentiation of the initial embryo cell layers that lineage-specific patterns of de novo 
methylation are established (41), (42). 
2.1.2. Role of DNA methylation in the regulation of gene expression 
The most important role of DNA methylation is the regulation of gene expression. There is abundant 
evidence that DNA methylation in the promoter region of genes correlates directly with transcription 
activity (43). An important line of evidence in demonstrating the suppressive potential of DNA 
methylation was provided using the cytosine analogue 5–aza-2’-deoxycytosin in cell lines. This 
cytosine substitute is efficiently incorporated into the cellular DNA but cannot be methylated due to the 
presence of a nitrogen atom at the 5’ position of the pyrimidine ring. Repressive states of several gene 
promoters could be reversed followed by activation of transcription of the associated gene (44). 
The mechanisms through which the methylation mediates transcriptional repression are both direct and 
indirect. Two biologically relevant mechanisms have thus far been described as being interdependent 
events leading to silencing at a certain genomic locus (Figure 2-1). 
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1.) Direct transcription repression is thought to occur by inhibiting the binding of transcription factors to 
their recognition sites in the respective promoters. This is presumably accomplished by protruding into 
the major DNA helix groove (45). Several transcription factors, including c-Myc/Myn, AP-2, cAMP 
dependent CREB, E2F and NF- B, recognise sequences that contain CpGs, many of which were 
shown to be methylation sensitive (46), (47).  
2.) Indirectly, methylated DNA recruits methyl cytosine binding proteins (MeCPs) which have been 
shown to bind to methylated CpG dinucleotides in any sequence context and to prevent further 
transcription factor binding. In addition, MeCPs mediate repressive chromatin remodelling by 
associating with large protein complexes containing co-repressors and histone deacetylases leading to 
heterochromatin formation in the respective DNA region (48). 
 
 
 
Figure 2-1 Proposed mechanisms of transcription repression mediated by DNA 
methylation. The left column shows the direct repression mechanisms through sterical inhibition of 
transcription factor binding. The right column shows the indirect mechanisms, where methylated DNA 
recruits methyl binding proteins and histone deacetylases thereby inducing a repressive chromatin status 
(Singal et. al 1999).  
2.1.3. DNA methylation in T-lymphocytes: role as epigenetic 
memory 
The immune system is a fertile field for studies of epigenetic regulation of cell fate and function as it 
allows for the obtainment of pure cell populations from nearly every step during adult blood cell 
development. There is evidence for epigenetic regulation of several key immune processes including 
lymphocyte development, antigen presentation, differentiation, cytokine expression, effector function, 
and memory. 
Introduction   Page 16 
One of the most intriguing questions is that of differentiation: how does a precursor cell give rise to 
daughter cells with a different set of expressed genes and further, by means of which mechanism is the 
daughter cell capable of remembering the inductive event leading to its phenotype? Epigenetic 
mechanisms, including DNA methylation, seems to partially answer this question. Current evidence 
that DNA methylation acts together with additional epigenetic processes to limit the probability of 
aberrant gene expression and to stabilize, rather than to initiate, cell fate decisions during lineage 
commitment has been provided. 
Human B-lymphocytes develop in the bone marrow. In contrast, T-lymphocytes travel undifferentiatedly 
to the thymus, later to lymph nodes and the body tissue. There, the final maturization takes place in the 
presence of MHC attached antigens. Both lymphocytes, B- and T-cells are generated in the adult 
organism from a common progenitor, the CD34+ hematopoietic stem cells located in the bone marrow 
and require a number of specific extracellular stimuli at each step to accomplish lineage commitment 
(36). Development to mature T-lymphocytes requires several intermediate steps during which 
rearrangements at T-cell receptor genes take place in early stages, followed by a “naive” cell status 
prior to antigen encounter and the selective induction of a restricted set of poised cytokine genes and 
stable silencing of other cytokines. Figure 2-5 schematically illustrates the individual differentiation 
steps that lymphocytes undergo during differentiation and maturization in their distinct lineages. 
T-lymphocytes differentiate first into cytotoxic CD8+ cells and CD4+ T-helper cells, the latter 
developing further into “effector” cells. These are categorised based on the secretion of non-
overlapping patterns of cytokines such as IFN-   (T-helper 1) or IL-4, IL-13 and IL-5 (T-helper 2) (49). 
DNA methylation is involved in the regulation of the two co-receptor genes CD8 and CD4. Progressive 
DNA demethylation occurs during differentiation from CD4-CD8- into CD8+CD4+ double positive 
thymocytes at the CD8 locus (50), (51) while in the parallel lineage the CD4 locus becomes 
demethylated leading to CD4+ thymocytes (52). Demethylation and expression induction occurs in 
activated CD8+ T-cell clones within the IL-3 promoter, with most of the demethylation occurring at a 
specific CpG site 164bp upstream of the transcriptional start (53). 
In naive CD4+ cells, the effector cytokines IFN-   and IL-4 exist in a restrictive chromatin structure but 
are not completely transcriptionally silenced. Activators such as lineage specific transcription factors 
can bind and induce low transcription activity. As the cells mature and differentiate into the two T-
helper cell subsets, regulatory elements in both genes, IFN-   and IL-4 become demethylated. In 
parallel, strong expression of the genes is induced and they remain in a heritable status of expression. 
This status appears to be “locked in”, since absence of the associated transcription factors in the 
mature cells does not result in transcriptional silencing of the respective cytokine. (54), (55), (56). 
Recently, demethylation at a single CpG site in the promoter of the IL-2 gene was demonstrated to be 
responsible for stably maintained IL-2 expression in activated T-cells (57). All of the above-described 
phenomena require iterated cell divisions through which the methylation signals at the specific sites are 
removed through the passive mechanism of repressed maintenance methylation.  
Although not the exclusive mechanism, DNA methylation obviously contributes to the establishment 
and memorization of transcriptional thresholds that vary between genes and T cell types. 
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2.1.4. DNA methylation in cancer 
The first indication, that DNA methylation is directly implicated in cancer formation was published 
already in 1979 (58). A few years later, Gama-Sosa et al. showed that the overall 5–methylcytosine 
content is strongly reduced (20 – 60% less) in tumor cells as compared to their normal counterparts, 
leading to the first connection between DNA methylation and cancer: global DNA hypomethylation in 
cancer (59). Global hypomethylation is defined as the genome wide reduction of the methylation 
content. It can lead to the transcriptional reactivation of intragenomic parasitic DNA otherwise 
repressed by DNA methylation, a common finding in tumorigenesis (60), (19). This phenomenon 
appears to begin very early in affected cells and thus to precede frank tumor formation (61). The direct 
effect of oncogene reactivation in the development of tumors has not yet been proven. Examples of 
demethylated oncogenes in neoplasia are the bcl-2 gene in B-cell chronic lymphatic leukaemia and the 
k-ras proto-oncogene in lung and colon carcinomas (62), (63). 
In parallel to the genome wide loss of methylation, several genes (including many critical to the tumor 
phenotype) display an increase in methylation during tumorigenesis. This process leads ultimatively to 
epigenetic silencing of expression and loss of protein function. 
A widely studied effect of DNA methylation in cancer, with implication to both diagnostics of cancer and 
therapy, is the hypermethylation of tumor-suppressor genes. Hypermethylation, the increase of 
methylation level at certain (usually CpG island associated) promoters, is considered to be a common 
hallmark of all types of human cancer, affecting genes involved in several cellular pathways. Affected 
pathways are: the DNA repair, the cell cycle, the cell adherence, apoptosis, detoxification and 
hormonal response pathways (64), (65). Recent publications have revealed genes that belong to the 
non–classical pathways such as developmentally active transcriptional regulator as targets for 
hypermethylation in several types of cancers (66). 
The transcription factors analyzed in this work represent a new class of genes previously not 
associated with hypermethylation in tumors. 
Interestingly, during tumor formation, specific CpG islands become hypermethylated in an otherwise 
globally hypomethylated surrounding of a cancerous cell. This specific de novo methylation is thought 
to be either directed at target DNA sequence motifs (67) or the consequence of clonal selection of the 
hypermethylated phenotype in response to an advantageous surrounding.  
In the last few years, an increasing number of genes have been characterized as genes in which 
associated promoter CpG islands are hypermethylated in cancer. DNA-methylation mapping has 
revealed unique profiles of hypermethylated CpG islands that are specific for each type of neoplasia. 
For example, the GSTP1 gene promoter hypermetyhlation occurs in 70-80% of prostate cancer cases, 
while hypermethylation of the BRCA1 gene is typical for breast and ovarian tumors but does not occur 
in any other tumor type (68). 
Further, loss of DNA methylation at imprinted or tissue specific genes (LOI) leading to the activation of 
an otherwise silent allele is a well established mechanism of gene activation in certain types of cancer, 
as recently reviewed (25).  
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Recently, it has been demonstrated that microRNAs that have tumor-suppressor function can also 
undergo DNA-methylation-associated silencing in tumor cells (69), (70). This finding might indicate an 
additional contribution of DNA hypermethylation events to cancer development. 
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2.2. DNA methylation measurement 
2.2.1. Measurement principles 
DNA methylation is a binary event at the level of a single stranded DNA stretch: a given cytosine 
residue within a CpG dinucleotide complex is either methylated or unmethylated. However, a genomic 
DNA sample is heterogeneous for two reasons. First, a double stranded DNA molecule can display 
hemimethylation at a specific CpG: one strand is methylated, the palindromic cytosine is unmethylated. 
Second, the individual cells within a given sample usually consist of a heterogeneous mix of DNA 
molecules. Therefore, analysis of the DNA methylation distribution in a given sample can be performed 
at different levels, depending on the desired level of information. One can analyse: (1) the methylation 
content, (2) the methylation level or (3) the methylation pattern of a genomic sample (71). Figure 2-2 
displays the different approaches for determining the desired methylation information from a given 
sample. 
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Figure 2-2 DNA methylation analysis principles. Horizontal bars represent double 
stranded DNA with the methylation mark either on both strands or on the single strand as 
hemimethylated DNA locus. The grey shaded areas represent the CpGs participating in the described 
measurement principle. Methylation content represents the total amount of methylated CpG in the 
genome; methylation level refers to the average methylation frequency at a single CpG while methylation 
pattern refers to a series of consecutive CpGs located in cis on a single DNA strand. (Laird, 2003). 
 
As suggested by its name, the methylation content delivers information on the total methylation amount 
of the nucleic acid within the analyzed sample. This type of information is useful for the determination 
of e.g. global hypomethylation in cancer and stem cells or the general comparison of methylation 
contents within different species. However, no site-specific methylation information can be derived from 
the methylation content. More useful with regard to the functional relevance of DNA methylation and its 
application in medical diagnostics is the determination of the methylation level or the methylation 
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pattern of a given genomic sample. Methylation level refers to the frequency of methylation at an 
individual CpG dinucleotide in the genome and may be important for quantifying differences at 
regulatory sequences. Further, the methylation patterns deliver detailed methylation information on a 
set of CpGs located within a DNA stretch of several hundred base pairs. Both methylation level and the 
methylation pattern can be generated as “profiles” whereby the methylation status across many sites in 
the genome, either at individual CpGs or within distinct sequence stretches, is collected. This is very 
useful when a panel of distinct markers is being employed for e.g. molecular classification of cancer 
subclasses. All analyses performed in the current study are profiles of DNA methylation levels of 
candidate genes. The direct bisulfite sequencing technique that was used (described in detail in the 
next chapter) allows for the parallel determination of DNA levels of series of CpGs located within a 
sequence stretch covered by a PCR fragment. The methylation level of each individual CpG site is 
determined independently. 
2.2.2. Detection methods 
2.2.2.1. Genome wide methylation content 
As already described, DNA methylation can be assessed independent of a specific sequence (genome 
wide methylation content) or sequence specific (methylation level and patterns). The genome wide 
methylation content can be determined by chromatographic methods like thin layer chromatography 
(72), HPLC (73), capillary electrophoresis (74) or by immunological techniques with e.g. anti 5-
methylcytosine antibody (75). 
2.2.2.2. Sequence specific methylation analysis 
Markers that are differentially methylated between samples of different origin are almost exclusively 
site and sequence specific methylation signals. They are expected to enable, either as a single 
markers or as part of a marker panel, clinical diagnostics based on DNA methylation in the near future. 
The currently available techniques can be roughly divided into two categories: restriction enzyme and 
bisulfite conversion based methods. 
 
Methylation sensitive enzymes 
A large set of methylation sensitive restriction enzymes is currently available for methylation detection. 
With few exceptions, most enzymes digest exclusively unmethylated DNA at their specific restriction 
site leaving methylated DNA intact. The identification of differentially methylated regions based on the 
generated restriction fragments can be performed on a genome wide scale. This is possible either 
through random amplification (methylation specific arbitrarily primed PCR, MS-APCR) or by ligation of 
DNA linkers and subsequent amplification. Comparison analysis between different samples is 
performed by techniques such as 2D-gel electrophoresis (restriction landmark genomic screening, 
Introduction   Page 21 
RLGS), subtractive hybridisation followed by sequencing (methylated CpG island amplification-
representational difference analysis, (MCA-RDA) or microarray hybridisation (differential methylation 
hybridization, DMH) (76), (77) (78), (79), (80). 
Disadvantages of all methods relying on methylation sensitive restriction are the incomplete enzymatic 
digestion and the necessity of a restriction site for detecting differences at a specific desired site.  
 
Methylation analysis of bisulfited DNA  
Sequence specific methylation measurement has been revolutionised by the introduction of sodium 
bisulfite conversion of DNA combined with PCR amplification techniques (81). The methylation 
information is thus converted to DNA sequence information: the reaction catalyses the specific 
deamination of unmethylated cytosine to uracil. In the subsequent PCR amplification, the uracil is 
replaced by thymine leading to a sequence polymorphism measurable by conventional genomic 
methods (Figure 2-3). 
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Figure 2-3  Bisulfite conversion of DNA. In the presence of sodium bisulfite, 
unmethylated cytosine is irreversibly converted to uracil through a series of intermediate products. 
 
Conversion of the cytosine base is only possible in single stranded DNA. Thus, genomic DNA must be 
denatured prior to the bisulfite reaction. Upon completion of the reaction, the two initially 
complementary DNA strands loose complementarity since previously unmethylated non-CpG cytosines 
are all converted to uracils. The strands are referred to as bisulfite 1 and bisulfite 2 strands. Both 
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strands carry the methylation information and both can be amplified to measure methylation levels. For 
subsequent amplification of bisulfite DNA sequence specific primers are employed. Depending on the 
applied detection principle used, the primers can either be located to cover CpG positions and thus to 
discriminate between methylated and non-methylated DNA already during the amplification step or 
within CpG depleted regions. With regard to the latter, the higher the content of non-CpG cytosines in 
the primer sequence, the better the selection for efficiently converted DNA. 
By converting genomic to bisulfite DNA one can determine methylation levels and methylation patterns 
as well as the profiles of both (Figure 2-2) and analyse them by several of the available methods. 
Restriction enzyme assays are used to specifically digest previously amplified bisulfited DNA, followed 
by fragment analysis by gel or capillary electrophoresis (combined bisulfite restriction analysis, 
COBRA) (82). 
Several real-time PCR applications are available for the quantitative analysis of methylation. 
MethylLight, for example makes use of sequence specific Taqman probes, which carry a fluorescence 
dye at the 5’ end, and a quencher at the 3’ end. If hybridisation is successful, the 5’-3’ exonuclease 
activity of the polymerase hydrolyses the probe and releases the dye thereby generating a detectable 
signal (83). Although this method is suitable for high throuput, the CpG density which can be analyzed 
is relatively low. 
Currently available methods developed for the analysis of DNA methylation have been reviewed by 
Laird, 2003 (71). 
A powerful high throughput technique enabling the simultaneous measurement of methylation levels at 
several CG dinucleotides is the direct bisulfite sequencing. The method has been heavily used in the 
current work. It involves the sequence specific amplification of bisulfited treated DNA and the 
immediate sequencing of the generated PCR products, without laborious subcloning procedures. The 
sequencing workflow, material ressources and costs are reduced and the sequencing throughput can 
be significanty increased. To quantitatively determine the mixed methylation signal resulting from 
heterogeneously methylated DNA special software was employed (84). 
The procedure of direct PCR product bisulfite sequencing involves a series of consecutive steps. The 
methylation level at a specific CpG site of an individual genomic DNA sample is transformed to a 
cumulative signal where methylated cytosines are detected as cytosines and unmethylated cytosines 
as thymine. The laboratory procedure involves the bisulfite treatment of the previously purified genomic 
DNA, the amplification of the desired genomic region by means of sequence specific primers, the 
sequencing and subsequent analysis and data representation by means of a methylation heat chart. 
The method steps from a heterogeneously methylated DNA sample to the quantitative methylation data 
representation are schematically shown in Figure 2-4. 
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Figure 2-4 Bisulfite sequencing workflow showed schematically for a heterogeneously 
methylated genomic sample. After bisulfite treatment (2), methylated cytosines remain cytosine while 
unmethylated cytosines are converted to uracil. Sequencing of the previously amplified genomic region 
(3 + 4) reveals overlapping C and T signals at each individual CpG position (5). Quantification of the 
peak areas after normalisation allows for the methylation quantification, which is subsequently colour 
coded and represented in a methylation heat chart (6). 
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2.3. Cytokines and transcription factors in the immune 
system 
2.3.1. The cytokines interleukin 10 (IL-10) and interferon-  (IFN- ) 
IL-10 
IL-10, alias cytokine synthesis inhibitory factor (CSIF) is an important regulatory cytokine with an 
overall immunosuppressive effect on the immune response. Many cell types including T-cells, 
monocytes, macrophages and dendritic cells, produce IL-10. Also, several subsets of regulatory T-cells 
(Treg) express IL-10. Tregs are suppressor T-cell types that have regulatory effects on the humoral 
and the cell-mediated immune responses and play an important role in the avoidance of allergic 
reactions and autoimmune disease (85). 
IL-10 exerts its inhibitory action on macrophages and dendritic cells, thereby regulating effector cell 
activation. However, it also has stimulatory effects on B and T-cells (86). IL-10-deficient mice develop 
severe chronic enterocolitis (87) while tissue or cell-specific overexpression of IL-10 leads to impaired 
immune responses (88), (89). Animal and human studies revealed that IL-10 is produced during 
pregnancy by the trophoblast, thus suggesting an important antiabortive role during pregnancy (90), 
(91). 
The expression of IL10 is under the control of several transcription factors such as Stat3 (92), Sp1 (93) 
and Sp3 (94), NF-κB (95), Smad-4 (96), c-Maf (97) and Jun proteins (98). However, there is still lack of 
understanding about the epigenetic events that regulate IL-10 expression in humans and there is only 
scarce information on the DNA methylation status of the promoter region. Recent data obtained on the 
IL10 gene accessibility with respect to DNase I hypersensitivity sites (HSS) have suggested chromatin 
remodelling of the gene locus in mice (99), (95), (100). This is of special interest, since the murine and 
human IL10 promoter show regions of high sequence similarity, refered to as conserved non-coding 
sequences (CNS) which have been shown to maintain regulatory functions. The IL10 promoter does 
not harbour a CpG island. 
In the present study an extended region 5’ upstream of the transcriptional start site and intragenic 
sequences of the IL10 gene are profiled for DNA methylation in subsets of human T-helper cells 
isolated directly ex vivo. Further, additional epigenetic marks such as histone modifications are 
analyzed at the IL10 locus. The DNA methylation status was assessed during several rounds of in vitro 
cultivation. 
 
IFN-  
IFN-   is a key cytokine produced primarily by natural killer cells (NK), CD8+ and CD4+ T lymphocytes. 
IFN-   facilitates host defense to intracellular pathogens and stimulates growth and differentiation of T- 
and B- cells, macrophages and NK cells. Further, IFN-   and Th1 lymphocytes were shown to prevent 
primary tumor development by regulating tumor cell immunogenicity (101).  
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IFN-   is part of the effector cytokine network in the immune response of T-helper 1 cells. Its presence 
leads to the inhibition of T-helper 2 cell activation. 
The regulation of this effector cytokine gene has been intensively studied over the last few years at the 
level of chromatin modifications, DNA methylation and DNase I hypersensitivity sites. Computational 
studies of interspecies DNA sequence comparison (human and mouse) revealed a highly conserved 
distal enhancer sequence located ~5kb upstream of the transcription start (102). This region has been 
shown to be DNAse I hypersensitive in Th1 cells but not in Th2 cells in the mouse. In addition, it is the 
binding site of two essential transcription factors: NFAT1 and the Th1 specific factor TBX21. 
Another DNase I hypersensitivity site with permissive chromatin status was found at 3.5kb upstream of 
the transcription start. This region was shown to be the binding site of the Stat5 transcription factor and 
its remodelling to be dependent on IL-2 (103). 
Studies on DNA methylation at the IFN   locus have shown the upmethylation of several CpG sites in 
non-expressing Th2 cells but a demethylated status of the same sites when IFN-   was expressed in 
Th1 cells. Furthermore, 5-azacytidine treatment of Th2 cells induced IFN-   expression, demonstrating 
an essential role for methylation in the tissue restricted regulation of the gene (104), (105).  
In this study a large stretch of the IFN   promoter and several intragenic CpGs mostly located in highly 
conserved sequence domains, were analyzed for DNA methylation in ex vivo human T helper cell 
subsets. In vitro experiments were performed where naive CD4+ T-cells were stimulated under 
different conditions to determine the optimal external stimulus and to describe the time course of site-
specific demethylation. The differentially methylated regions were used to quantify Th cell balances in 
CD4+ memory cell subsets of patients with rheumatoid arthritis and to compare them to healthy 
individuals. Further, the methylation status of these regions was assessed in the DNA obtained from 
endometrial biopsies of patients with endometriosis. 
2.3.2. Transcription factors 
The importance of proper orchestration of transcription factors (TFs) expression in normal 
hematopoietic development has been highlighted by experiments showing that altered quantitative 
expression of a single TF can lead to leukaemia (106), (107). The observation that many TFs are 
expressed in a lineage-specific manner makes them potential candidates for epigenetic control through 
e.g. DNA methylation. However, little is yet known about the epigenetic mechanisms involved in the 
regulation of these genes. 
In patients with hematological malignancies, TFs are frequently mutated or aberrantly regulated (108), 
(109). Thus, it may be hypothesized that aberrant promoter methylation of these genes could represent 
one mechanism contributing to hyperproliferation and in some cases to malignant transformation. 
Transcription factors (TFs) and their interactions within signalling pathways are key in the regulation of 
lineage commitment as well as the maturation of human hematopoietic cells, and act at various stages 
(110), (111). For example, the Wnt / beta-catenin signalling transcription factor TCF7 is required to 
maintain the pluripotent status of progenitor cells (112). Notch-1 is essential for intrathymic T-cell 
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lineage commitment and subsequent T-cell development (113). Other TFs are required to confer 
lineage specificity, such as Eomes for CD8+ cells, TBX21 for CD4+ T-helper 1 cells (114) and STAT6, 
GATA3 and c-maf for CD4+ T-helper 2 cells (49).  
In this study, the role of DNA methylation during hematopoietic development was analyzed through 
DNA methylation profiling, focusing on a set of 13 key TF genes (Figure 2-5). 
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Figure 2-5  Simplified scheme of human adult lymphopoiesis. The stage-specific 
expression of various transcription factors analyzed in the present study is shown. For simplicity, the 
expression pattern of some genes and cell types has been omitted. In total, 13 transcription factors were 
analyzed: SPI1, c-maf, TCF7, FOG1, NOTCH1, Th-POK, GATA3, Hlx, TBX21, Eomes, Stat1, Stat6 and 
Etv5. Common lymphoid progenitors (CLPs) differentiate to either B-cell (left branch) or to CD4+/CD8+ 
double positive (DP) lymphocytes (right branch). CD4+: CD4+ lymphocytes, CD8+: CD8+ lymphocytes, 
Th1: T-helper 1 cells, Th2: T-helper 2 cells.  
 
The selected TF genes included those expressed during early lymphoid development (TCF7, STAT6, 
GATA3 and SPI1 (PU.1) (Gomes et al., 2002)), as well as Th2 - (GATA3) and Th1 specific factors 
(Hlx1, STAT1). Other factors such as c-maf and TBX21 are expressed in both CD8+ and CD4+ 
lymphocytes. In addition, CD8+ specific factors were selected (eomes), factors which are involved in 
early thymocyte development (Notch-1) and later CD4/CD8 (Th-POK) lineage determination (115), 
(116) and co-activators such as FOG-1 (117). Etv5 (ERM) is expressed in naive and Th1 CD4+ 
lymphocytes (118) and was selected because of its drastic up-regulation during neoplastic B-
lymphocyte development (119). 
DNA methylation profiles of the above genes were assessed in healthy hematopoietic progenitor cells 
and in selected stages and lineages of T- and B-lymphocytes. The aim was to determine if, and at 
which specific CpG position the methylation information changes during development and lineage 
commitment. To determine if the profiled TF genes were aberrantly methylated in lymphomas, all 
genes were analyzed on DNA from lymph node biopsies of two non-Hodgkin lymphoma entities: a B-
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cell neoplastic disorder (diffuse large B-cell lymphoma, DLBCL) and T-cell non-Hodgkin lymphoma (T-
cell NHL). 
2.4. DNA methylation as diagnostic tool 
Interest in DNA methylation has experienced a boom in the last few years as its relevance in human 
malignancies has become evident. DNA methylation markers have a promising future in both clinical 
diagnostics and therapeutics but yet are restricted almost exclusively to cancer. In cancer research, the 
term “marker” or “biomarker” refers to a substance or process that is indicative of the presence of a 
certain cancer phenotype in the body. 
The primary diagnostic applications are obvious but they can also influence the therapeutical options 
as several methylation markers have been described to be predictive of response to therapy through 
stratification of patient groups (71). As methylation is an early event in carcinogenesis the identified 
markers have the potential to be early indicators of existing disease and thus can be of tremendous 
importance in cancer diagnostics.  
DNA methylation is, in contrast to gene expression, a very stable modification of the DNA. It can be 
measured in samples obtained by non-invasive methods such as in body fluids (blood, plasma, 
sputum, urine, etc.) through detached cancer cells or through the free floating DNA that is released 
from apoptotic or necrotic tumor cells (120), (121). However, the prerequisite for this type of sensitive 
measurement is a marker which is specifically hypermethylated in cancer cells but hypomethylated in 
“normal” cells. 
2.4.1. Rheumatoid arthritis (RA) 
Rheumatoid Arthritis (RA) is a crippling disease that affects 0.5 % of the population, mainly women 
(3:1) in the prime of their life (onset either between 35 – 45 y or after 60, sometimes at childhood age). 
It is a chronic inflammatory autoimmune disorder which leads to the accumulation of inflammatory T-
cells in the synovial membrane of joints and ligaments. The consequence being that the immune cells 
induce an injury response in the joint, which in turn leads to the formation of tissue (pannus) that is 
invasive and has a destructive character. 
The articular inflammation in RA causes activation and proliferation of the synovial lining, expression of 
inflammatory cytokines, chemokine-mediated recruitment of additional inflammatory cells, as well as B 
cell activation with autoantibody production. The measurements of cytokine levels in the synovium of 
RA patients has revealed a broad range of highly expressed macrophage and fibroblast cytokines such 
as IL-1, IL-6, IL-15, IL-18, TNF-α, granulocyte – macrophage colony stimulating factor (GM-CSF) and 
several chemokines.  
The naturally occurring suppressor cytokines including TGF-
 
, IL-1Ra and IL-10 are expressed at 
levels that are insufficient to block the destructive process. 
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The role of DNA methylation has so far not been studied in RA. Since the pathological mechanism 
requires strong overexpression of pro-inflammatory cytokines, a defective expression control within 
these genes is probable.  
The clinical diagnosis of RA is complex and currently cannot be performed by means of a single test. 
Instead, it is an evaluation of several parameters gathered from patient history, physical examination, 
blood tests and RA-specific molecular diagnostic testing of patient serum. A non-invasive and highly 
specific serum based test is needed to quickly diagnose and efficiently treat the disease.  
Studies on the peripheral blood of RA patients described a disturbed Th1 / Th2 cell balance, whereby a 
reduction of Th1 cells as compared to Th2 cell was frequently detected (122), (123). 
In the present work a DNA methylation marker was efficiently used to quantify the Th1 / Th2 cell ratio in 
the CD4+CD45RO+ (memory) cell compartment of peripheral blood of RA patients and healthy 
volunteers. 
2.4.2. Endometriosis 
Endometriosis is a common gynecological disease, which affects about one out of ten women of 
reproductive age. Characteristic of this disease is the presence of endometrial glandular tissue outside 
of the uterus. Despite this seemingly simple indication, it is a complex disease, which even today is 
only poorly understood regarding its etiology and development. The disease is responsible for various 
types of pelvic pain and infertility. Despite the enormous research efforts in this field, the etiology of 
endometriosis remains poorly understood. 
The diagnostic gold standard is laparoscopy, a surgical procedure unpleasant for the patient and 
expensive to perform. Overall the disease remains underdiagnosed and even when finally diagnosed a 
delay of seven years or even longer between disease onset and diagnosis is common. The role of DNA 
methylation has so far not been studied in any detail in this disease.  
In this study, results are presented where DNA methylation was measured at the cytokine gene loci of 
IFN-   and IL-10 in patients with and without endometriosis. The sample material was endometrial 
biopsy tissue from women with laparoscopically confirmed or rejected endometriosis diagnosis. The 
results are part of a large marker scanning study aimed at developing a methylation based minimally 
invasive endometriosis diagnostic test. 
2.4.3. Non–Hodgkin lymphoma 
Malignant lymphomas are proliferative diseases that arise from the lymph nodes or extranodal 
lymphatic tissue. According to the variety of stages involved in the maturation and differentiation of the 
lymphatic cells a number of different types of lymphomas exist (124). 
The name “non-Hodgkin lymphoma” was introduced to separate distinct disease entities with respect to 
their morphological and clinical features. The origin of the malignant cells in Hodgkin lymphoma (Reed 
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Sternberg cells) was for a long time a matter of discussion and it is only recently that they were 
assigned B-cell properties, which makes it now a clonal B-cell neoplasia (125). 
Classical non-Hodgkin lymphoma are categorised by the origin of the predominant immunologic cell 
type found in the affected lymph nodes as determined by immunohistochemical methods. The disease 
categories include B-cell lymphomas, T-cell and natural killer cell lymphomas. Each subtype is further 
divided into precursor cell neoplasia and peripheral cell neoplasia. 
In the present study biopsy samples of B- and T-peripheral cell lymphomas were analyzed. More 
specifically peripheral cell diffuse large B-cell lymphoma (DLBCL) and peripheral cell pleomorphic 
small / large T-cell non-Hodgkin lymphoma (T-cell NHL) were analyzed. Both classifications are 
clinically heterogenous and molecular markers which allow further stratification of patient groups with 
regard to therapy efficiency are being investigated (126). 
As in other neoplasias, an important component of the cell biology of malignancy is inherited from its 
non-transformed progenitor. Each of the currently known T- and B-cell neoplasias has been traced 
back to particular stages of differentiation of the two lineages.  
Two DNA methylation aberrancies have been detected in lymphomas: global genomic hypomethylation 
and CpG island hypermethylation. The vast majority of haematological neoplasms have an overall 
genomic hypomethylation as compared to their normal counterparts. 
As described in the chapter 2.1.4, specific hypermethylation events can be assigned to lymphoma 
entities that do not occur in other cancers leading to a specific lymphoma “methylotype”. Figure 2-6 
provides an overview of the most frequently methylated tumor suppressor genes in lymphomas. 
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Figure 2-6 Percentage of CpG island hypermethylation of common tumor suppressor 
genes in lymphoma (Esteller, 2003) 
 
Recent studies in myeloid leukaemia have suggested that aberrant expression of transcription factors 
are the cause of malignant cell transformation (127). Since transcription factors have a pivotal role in 
the establishment of hematopoietic lineages and act at very early stages of differentiation, it is plausible 
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that mechanisms disturbing appropriate transcription of transcriptional factors, including silencing by 
DNA methylation, may lead to developmental defects and cancer. 
The present study is aimed at investigating the methylation patterns of specific transcriptional factor 
genes with regard to promoter hypermethylation in the above described lymphoma subtypes and 
comparing them to their normal counterparts, the cells in healthy lymph nodes. 
2.5. Scope of the current project 
Providing a detailed analysis of the role of DNA methylation in the immune system is the major aim of 
the current study. Designated candidate genes encoding important signalling molecules (cytokines) 
and transcriptional regulators were analyzed by methylation profiling techniques and, as for the IL10 
gene, several epigenetic features characterising the locus were analyzed.  
Since diagnostic biomarker discovery was one issue in this work, the candidate genes in both gene 
classes, cytokines and transcription factors, were selected following a tailored biomarker candidate 
discovery strategy. The diagnostic performance of the identified differentially methylated regions was 
assessed in three major disease entities: rheumatoid arthritis, endometriosis and Non Hodgkin 
lymphoma. 
The study was divided into two major sections: (1) cytokine and (2) transcription factor genes and the 
candidate genes of each class were analyzed, in part, in different cell types. Experiments were 
performed in order to provide answers to the following questions: 
  
 To what extent is DNA methylation involved in the memorization and induction of transcription in the 
IL10 and IFNγ  genes? 
 How is the chromatin landscape of the IL-10 gene in both IL-10+ and IL-10- cells defined? 
 Is DNA methylation an epigenetic memory tag for an aquired expression phenotype? 
 Is the methylation pattern of cytokine genes subject to alterations in vitro under expansion and / or 
differentiation conditions? 
 Do differentially methylated regions differentiate between healthy and disease states in conditions 
such as rheumatoid arthritis or endometriosis? 
 Is DNA methylation at transcription factors genes subject to change as cells develop and 
differentiate? 
 To what extent does the methylation pattern of transcription factors correlate to their expression? 
 Are the same regions aberrantly hyper- or hypomethylated in B-cell and T-cell neoplasms and do 
they represent a novel type of DNA methylation marker associated with defective transcriptional 
machinery in lymph node neoplasia? 
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3. Methods 
3.1. Cell samples 
3.1.1. Isolation of human CD4+ / CD8+ T–lymphocytes and CD19+ 
naive and memory B-lymphocytes 
Buffy coats from healthy adult anonymous donors were obtained in accordance with local ethical 
committee approval (DRK-Blutspendedienst, Berlin und Brandenburg GmbH, Institut Berlin, Germany). 
Peripheral blood mononucleated cells (PBMCs) were isolated from the buffy coats by density gradient 
sedimentation using Ficoll-Hypaque. Cells were washed twice with 50 ml phosphate buffered saline 
(PBS) before CD4+ and CD8+ T-cell separation. CD4+ and CD8+ T-cells were purified from PBMCs by 
magnetic activated cell sorting (MACS) using CD4 and CD8 MicroBeads respectively, according to the 
manufacturers recommendation. The efficiency of the purification was verified by staining with FITC 
conjugated antiCD3, antiCD8 and antiCD4 antibodies (BD Tritest™) (10µl / 5x105 cells) for 30 min on 
ice. Fluorescence of the labelled population was determined by a FACScalibur™ instrument using the 
CELLQuest™ software. The purity of each of the sorted populations was 98%. 
CD19+ B-cells were purified from PBMCs by MACS using CD19 MicroBeads. The purity of the sorted 
population was 95% as determined by FACS using FITC conjugated antiCD19 antibodies using 10µl 
antibody solution for 5x105 cells. Naive B-cells (CD19+CD27-) were separated from memory B-cells 
(CD19+CD27+) subsets by using CD27 MicroBeads. 
3.1.2. Isolation and characterisation of T-helper cell subsets 
secreting IL-10 and IFN-   
3.1.2.1. Isolation of T-helper memory cell subsets secreting IL-10 and IFN-  
Highly purified human CD4+ T-lymphocytes from 30 individual healthy donors were stimulated with 
5ng/ml Phorbol 12-myristate 13-acetate (PMA) and 1µg/ml Ionomycin (I) at 1x107 cells per ml for 4 
hours. After stimulation, cells were washed with ice-cold buffer (PBS with 0.5% BSA and 2mM EDTA), 
and labelled with IL-10 or premixed (1:1) IFN-γ and IL-10 specific capture matrix in cold medium for 5 
minutes on ice. Subsequently, the labelled cells were diluted in pre-warmed medium ( 105 cells/ml) 
and subjected to a 45-minute cytokine secretion period at 37°C under slow continuous rotation. The 
cytokine secretion was stopped by filling up the tube with cold buffer and subsequent incubation on ice 
for 15 minutes. Cells were harvested and surface stained with specific detection antibodies for IL-10 
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(conjugated with either APC or PE) or equal amounts of specific detection antibodies for IL-10 
(conjugated with either APC or PE) and IFN-γ (conjugated with FITC). Subsequently, four distinct Th-
cell subsets were detected and isolated: IL-10+/IFN-γ-, IL-10-/IFN-γ+, IL-10+/IFN-γ+ and IL-10-/IFN-γ- 
using either single or double cytometric cytokine secretion assay on a FACSDiva. Age and gender of 
the 30 healthy donors as well as their distribution within the pools are shown in Table 3 in the 
appendix. All donors were caucasians. 
3.1.2.2. Cytometric bead array (CBA) assay for assessing cytokine expression 
in ex-vivo T-helper cell subsets 
Supernatants from 48-hour or 72-hour cultures of PMA/I stimulated Th-cell subpopulations were 
analyzed by the human Th1/Th2 cytokine CBA Kit, which allows the simultaneous detection and 
quantification of soluble IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ in a single sample. In brief, a mixture of 
10 µl of each of the six different bead suspensions specific for each cytokine (resolved in FL3 channel), 
was incubated with 50 µl of sample and 50 µl of PE-conjugated detection antibody (resolved in FL2 
channel) for 3 hours. Acquisition of sample data was performed using a FACScalibur™ and results 
were analyzed using the Becton Dickinson CBA analysis software. 
3.1.2.3. In vitro expansion of T-helper cell subsets 
Sorted Th-cell subsets were seeded in a 96-well plate (2x104 cells/well) (without feeder cells). Different 
combinations of cytokines were added twice during the expansion. Cytokine profiles were assessed at 
day 8, after 6 hours of PMA/I stimulation (the last 4 hours with brefeldin A) and by intracellular cytokine 
staining for IFN-γ and IL-10 and FACS analysis. 
3.1.3. In vitro expansion and differentiation of naive CD4+ T-cells 
3.1.3.1. Isolation of naive CD4+ T-cells from PBMCs 
PBMCs were isolated from buffy coats obtained from healthy adult anonymous donors by density 
gradient sedimentation using Ficoll-Hypaque. CD4+ T-lymphocytes were purified from the PBMCs by 
magnetic activated cell sorting (MACS) using CD4 MicroBeads. Naive Th-cell subsets were 
subsequently sorted from CD4+ cells using CD45RA/RO isoform MicroBeads. The purity of sorted 
population was 99%, as determined by FACScalibur™ using the CELLQuest™ Software. 
3.1.3.2. Purification of monocytes and generation of dendritic cells 
CD14+ monocytes were purified from PBMCs by MACS using CD14 MicroBeads. Sorted monocytes 
were cultured in the presence of 1000 U/ml GM-CSF and 500 U/ml rIL-4 for 5 days at 1.0 x 106 cells/ml 
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in 5 ml final volume and then matured with LPS for 2 days. Maturation was monitored by induction of 
CD80, CD83 and CD86 expression on cultured monocytes, as follows: cultured cell populations were 
washed twice with PBS and centrifuged at 1500 g (3200 rpm) for 3 minutes. After removing the 
supernatant, cells were resuspended and 150 mg mouse IgG was added to the cell suspension for 15 
minutes to prevent non-specific binding of reagents to Fc receptors. Following the incubation period, 
100ml of cell suspension was added to fluorochrome-conjugated reagents (FITC-anti CD14, PE-anti 
CD80, PE-anti CD83 and PE-anti CD86) and cells were incubated in the dark for 15 minutes after light 
vortexing. Cells were washed and fixed with 200ml 2% formaldehyde. Stained cells were analyzed by a 
FACScalibur  
3.1.3.3. Differentiation of naive CD4+ T-cells into IFN-γ producing cells 
Naive CD4+ Th cells were stimulated with either: 
1. plate-bound anti-CD3 and anti-28, in the presence of rIL12 and anti-IL-4 (stimulus I) 
2. plate-bound anti-CD3 and anti-28, in the presence of rIL12, anti-IL-4 and IFN-γ (stimulus II)and 
3. alloDC (generated as described in chapter 3.1.3.2) (stimulus III) 
for 7 days.  
The cells were re-stimulated with PMA / Ionomycine for 4 hours followed by IFN-γ capture assay. IFN-
γ-producers were separated from non-producers via FACS with a purity higher than 95% for each 
subpopulation. 
3.1.4. Isolation of human IFN- + CD4+ cells from patients with 
rheumatoid arthritis 
3.1.4.1. Naive and memory cell isolation 
PBMCs from nine patients were isolated from 20-50 ml heparinized blood, while PBMCs from six 
healthy donors were isolated from buffy-coated blood preparations by density gradient sedimentation 
using Ficoll-Hypaque. CD4+ T cells were purified from PBMCs by MACS using CD4 MicroBeads. 
Subsequently, over 95% pure naive and memory CD4+ T cells were isolated using CD45RA and 
CD45RO MicroBeads respectively. 
3.1.4.2. Isolation of IFN-  producing cells 
CD45RO+CD4+ memory T-cells were stimulated with PMA and ionomycin for 4-6 hours, in the 
presence of 5 µg/ml brefeldin A for the last two hours. The stimulated cells were then fixed with 2% 
formaldehyde, permeabilized with 0.3% Triton-X-100 in PBS and stained intracellularly for IFN-  . 
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Alternatively, IFN-   producers and non-producers were FACS sorted after 4 hours of PMA and 
ionomycin stimulation and cytokine secretion assay. 
3.1.5. External sample sources 
3.1.5.1. Primary hematopoietic cells 
Bone marrow derived hematopoietic progenitor cells (CD34+) from two female donors (caucasian, age 
30y and asian, age 36y) and one male donor (caucasian, age 21y) were purchased from Cambrex Bio 
Science (Walkersville, Maryland, US). 
3.1.5.2. Human T-helper cell clones 
Human IL-10+ and IL-10- Th1 and Th2 clones were obtained from the group of Francesco Annunziato 
from the Center of Research Transfer, High Education MCIDNENT, University of Florence, Italy and 
were cultivated there as previously described (128), (129). 
3.1.5.3. Lymph node biopsies 
Lymph node biopsies from diffuse large B-cell non-Hodgkin lymphoma (n = 20, mean age 67 ± 7 years) 
T-cell non-Hodgkin lymphoma (n = 14, mean age 63 ± 9 years) and healthy individuals (n = 18, mean 
age 69 ± 10 years) were obtained from one of the following sources: Ardais, (Lexington, US), 
Phylogeny (Columbus, US), Asterand Inc. (Detroit, US) and Benjamin Franklin University hospital 
(Berlin; Germany). Only anonymized samples were used and ethical approval was obtained for the 
study. All samples were histologically examined and confirmed to have a tumor cell content of > 85% in 
case of positive NHL / Hodgkin disease diagnosis and to be free of malignant cells in the normal 
controls. 
3.1.5.4. Lymphoma and leukaemia cell lines 
The following human leukaemia and lymphoma cell lines were used for gene expression and 
methylation measurements: Jurkat clone E6-1 (T-lymphocytes derived from acute T cell leukemia, 
ATCC TIB-152), KARPAS-299 (lymphoma cell line of T-cell origin, DSMZ ACC 31), SU-DHL4 
(lymphoma cell line of B-cell origin DSMZ ACC 495) and Z-138 (leukemia cell line of B-cell origin) 
(130). KARPAS-299 and SU-DHL4 were cultured in RPMI 1640 with 10% fetal calf serum (FCS) and 
2mM L-glutamine. Z-138 was cultured in DMEM with 10% fetal calf serum and 2mM L-glutamine. 
Jurkat clone E6-1 was cultured in RPMI 1640 with 10% fetal calf serum, 2mM L-glutamine, 10mM 
HEPES and 1.0mM Sodiumpyruvate. 
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3.1.5.5. Endometrial biopsies 
Tissue from endometrial biopsies of women with laparoscopically confirmed endometriosis was 
purchased from Cureline Inc. (Seattle, USA). The time point of extraction of each sample was the 
secretory cycle phase. 
3.2. Direct bisulfite sequencing 
3.2.1. DNA extraction and quantification 
3.2.1.1. DNA extraction from peleted cells 
Genomic DNA from all lymphocyte samples and the cell lines was extracted using the QIAamp DNA 
Mini Kit from Qiagen. Peleted cells were resuspended in 200µl PBS and lysed using the 
manufacturer’s cell lysis buffer (AL), 40U Proteinase K and 20U RNAseA for 4h at 37°C. After the lysis , 
the genomic DNA was isolated and purified according to the manufacturer’s recommendations. The 
elution of the DNA was performed with 60µl of prewarmed (50°C) buffer AE. Quantification of the 
eluted DNA was performed at 260nm using an Eppendorf UV spectrophotometer. 
3.2.1.2. DNA extraction from lymph node biopsies 
Each 20mg sample of frozen lymph node biopsy tissue was lysed by incubation with tissue lysis buffer 
(TLB) (Qiagen) in combination with 40U Proteinase K over night (16h). Subsequently, the genomic 
DNA was isolated using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturers protocol. 
Elution of the DNA and subsequent quantification was performed as described for the peleted cells. 
3.2.1.3. DNA quantification  
The amount and the purity of isolated genomic DNA and bisulfite treated DNA was assessed by UV 
spectrophotometrical measurements at    = 260nm (nucleic acids) and    = 280nm (proteins). 
A minimum of 50µl of genomic DNA were measured in a UV spectrophotometer in disposable cuvettes 
of 10 mm thickness and the concentration (ng/µl) was obtained according to the Lambert – Beer law by 
multiplying the optical density with the factor 50. Protein contamination was assessed by determining 
the ratio of the optical densities at 260nm and 280nm.   
Bisulfite treated DNA was quantified using a NanoDrop® ND-1000 spectrophotometer. 1.5µl of bisulfite 
converted DNA was used for measurement and the obtained optical density was multiplied by the 
factor 33, as converted DNA is single stranded. The purity of the samples was monitored on the 
recorded UV-spectrum (from 160 – 300 nm). In the presence of peaks other than at 260nm, the DNA 
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solution was re-purified on a Microcon YM30 centrifugal filter device by washing with water and re-
suspending in fresh TE-buffer. 
3.2.2. Preparation of bisulfited DNA 
3.2.2.1. Preparation of reference upmethylated and unmethylated DNA 
For accurate quantification of the individual methylation levels at the investigated genomic loci, DNA 
standards of known methylation levels were generated. This was prepared by mixing defined amounts 
of artificially up- and downmethylated DNA and subsequent sequencing. 
Unmethylated (0% methylation) DNA was generated by the molecular stand displacement method 
(131), using the GenomiPhi® DNA Amplification Kit according to the manufacturers instructions on 
isolated human genomic DNA from peripheral blood lymphocytes (Promega). 
Artificially upmethylated DNA (100% methylation) was generated by enzymatic treatment of the 
previously generated unmethylated DNA with a DNA methylase (SssI metyhlase) in the presence of S-
adenosylmethionine (SAM). 10µg unmethylated DNA were incubated with 40U SssI methylase and 
1.24µl SAM in a final volume of 100µl for 16 hours at 37°C in the Eppendorf 5355 Comfort 
thermomixer. 
Both DNAs the methylated and the unmethylated were bisulfite treated, spectrophotometrically 
quantified by the NanoDrop spectrophotometer and mixed according to obtain DNAs of 10%, 20%, 
50% 70% 80%and 90% methylation. 
3.2.2.2. Bisulfite reaction 
The bisulfite conversion of the analyzed DNAs was performed according to an enhanced protocol 
developed at Epigenomics AG (132) based on the original method reported by Frommer et. al (81).  
An amount of 1µg-2µg genomic DNA dissolved in 100µl DEPC treated water was incubated with 354µl 
bisulfite solution containing: 
0.4708 g/ml Sodium bisulfite Na2S2O5, 
0.1128 g/ml Sodiumsulfite Na2SO3 and 
146µl dioxane solution containing 39.4 mg/ml 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 
as radical scavenger. 
The mixture was incubated in a DNA Engine Tetrad® thermocycler with the following cycler program: 3 
min at 99°C (denaturation of the DNA.), 1.5h at 60° C (conversion reaction), 3 min at 99°C (second 
denaturation step), 1.5h at 60°C (conversion reacti on), 3 min at 99°C (third denaturation step) and 2h  
at 60°C (conversion reaction). Subsequently, the re action mixture was diluted with 200µl water and 
purified by means of Microcon YM30 centrifugal filter devices. 
The purification consisted of six centrifugation steps at 14.000g for 12 min each. First, the reaction 
mixture was centrifuged to recover the DNA on the filter membrane. Subsequently, the recovered DNA 
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was washed with 0.2M NaOH (400µl) solution for removal of excessive sulfite and three times with 
DEPC treated water (400µl). The purified bisulfited ssDNA was eluted in 50µl-75µl prewarmed TE 
buffer and quantified on a NanoDrop spectrophotometer.  
The advantages of this bisulfite protocol are the high conversion rates, the reproducibility and the high 
DNA recovery after purification. 
3.2.3. DNA amplification 
PCR amplification was performed using primers designed specifically for bisulfite converted DNA and 
flanking the desired regions of interest on the individual bisulfited DNA. The primers with a minimum 
length of 19 bp and an annealing temperature of 55°C ± 2°C were manually designed and ordered 
without additional labelling at MWG Biotech. The target sequence of the designed primers contained 
no CpGs thus allowing unbiased amplification of methylated and unmethylated DNAs. Primer 
functionality was confirmed by sequencing the generated PCR product on the reference DNAs 
described in chapter 3.2.2.1 and a standard human genomic DNA (Promega). Primers that gave rise to 
an amplificate of the expected size when using genomic DNA as template were discarded, thus 
ensuring the specificity for bisulfite-converted DNAs. Each amplification was performed by means of a 
single primer pair (singleplex – PCR). A comprehensive list of all primer sequences used in the present 
study is given in Table 1 and Table 2 in the appendix, including the individual genomic positions, the 
amplicon length and the number of CpGs analyzed within the designated region. 
The reaction was performed on 96 well microtiter plates in a total volume of 25µl. The reaction 
composition was as follows: 10ng of bisulfite converted DNA, 2.5µl 10xPCR buffer (Qiagen), 5 pmol 
dNTP’s (each), 12.5 pmol forward primer, 12.5 pmol reverse primer and 1U of HotStart Taq 
polymerase. Water was added to obtain a final volume of 25µl. The cycling reactions were performed 
in a DNA Engine Tetrad® thermocycler. The following temperature profile was used for all 
amplifications: one heating step of 15 min at 95 °C  (initial activation of the polymerase) and 45 cycles 
with 20 s denaturation at 95 °C, 45 s at 55 °C (pri mer annealing) and 30 s at 72 °C (chain 
polymerisation). A final step of 10 min at 72°C aft er the 45 cycles was performed to ensure complete 
polymerisation. The obtained PCR product was briefly analyzed by electrophoresis on a 1.5% agarose 
gel and used in the subsequent sequencing reaction. 
3.2.4. PCR product purification and sequencing 
Previous to sequencing, the PCR products were purified in order to remove excess dNTPs and 
primers. For purification, 5.0µl of the PCR product were incubated with 2.0µl of a mixture of 
exonucleaseI and shrimp alkaline phosphatase (ExoSAP IT) for 45min at 37°C. Excess primers are 
degraded by the exonuclease and excess nucleotides are dephosphorylated by the alkaline 
phosphatase. The enzymes were denatured by heat inactivation for 15 min at 95°C subsequent to the 
reaction incubation. Both incubations were performed in a DNA Engine Tetrad® thermocycler.  
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The sequencing reaction was performed by means of the di-deoxy method described by Sanger et al. 
(1977) (133). The sequencing chemistry used was the BigDye Terminator V3.1 containing fluorescence 
labelled ddNTPs and the DNA polymerase. The reaction was performed by mixing following 
components: 
5.0µl of the ExoSAP IT digested PCR product (DNA content was not previously quantified) 
1.0 µl BigDye Terminator V3.1 containing labelled ddNTPs, 
4.0µl Sanger buffer, 
5.0µl dNTP mix (0.02mM each) and  
5µl sequencing primer (2mM)  
in a total volume of 20µl. 
The reaction mixture was incubated in a DNA Engine Tetrad thermocycler and subjected to the 
following temperature profile: 2 min at 96°C (initi al denaturation) followed by 25 cycles of 30 sec at 95°, 
15 sec at 55°C (primer annealing) and 4 min at 60°C  (elongation). 
The sequencing reaction was subsequently purified to remove unincorporated dye terminators 
(ddNTPs) by gel filtration spin plates DyeEx™ 96 according to the manufacturers protocol. Briefly, the 
total reaction volume was pipetted on the gel bed and centrifuged on an Eppendorf 5810 tabletop plate 
centrifuge for 5 min at 910 g. Prior to analysis by capillary electrophoresis, 10µl of Hi-Di® formamide 
was added to each sample well to ensure proper denaturation. The electrophoresis was carried out in a 
3730 ABI DNA Analyser. The length of the capillaries used was 36 cm (3730 DNA Analyzer Capillary 
Array) filled with the POP-7™ polymer. The electrophoretic conditions were the following: oven 
temperature: 60°C, injection voltage: 1.2 kV, injec tion time: 15 sec, running voltage: 8.5 kV, running 
time: 2450 sec. The resulting sequence traces were called by the integrated ABI KB basecaller. The 
quantitative methylation information at CpG positions was determined by a subsequent software based 
analysis (ESME). 
3.2.5. Software based methylation quantitation 
The analysis of all resulting tracefiles was performed by means of in-house developed software 
(ESME) (84) after basecalling with the intrinsic ABI basecaller. 
Briefly, after regular basecalling, the bisulfite specific analysis software performs signal normalisation, 
corrects for incomplete bisulfite conversion and aligns the positions in the trace file to the reference 
sequence in the database. After these initial processing steps, the methylation levels are calculated by 
comparing areas of overlapping C and T signal peaks at CpG sites. The procedure allows 
discrimination between levels of methylation that differ by 20%. The calculated levels are depicted in a 
colour-coded matrix. The rows of the matrix represent the methylation level for individual CpG sites 
while columns represent averages of triplicate sense sequencing for various cell types.  
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3.2.6. PCR product cloning and sequencing 
For the high resolution methylation analysis on region 5 of the IL10 gene (chapter 4.1.3.2), PCR 
products generated on bisulfited DNA of individual donors were subcloned into the TA cloning Kit 
(Invitrogen) following the manufacturers recommendation. Individual E. coli clones were picked, re-
cultured in LB medium and plasmid DNA extraction was performed using the plasmid mini Kit (Qiagen), 
again following the manufacturers instructions.  
The cloned PCR product was sequenced from the plasmid as template, without prior amplification by 
means of the same primer assay as used for its generation. Sequencing and trace file analyis were 
performed as described in the chapter 3.2.4.  
Donors used for the amplification and cloning of the IL10 region 5 DNA are listed in the Table 5 (7.5.2) 
3.3. Real time mRNA expression quantification assays 
3.3.1. mRNA extraction and cDNA preparation 
Total mRNA from the four analyzed cell lines was isolated by means of the RNeasy Kit according to the 
manufacturer’s protocol.  
The isolated mRNA was converted to cDNA by means of the Omniscript Reverse Transcription Kit. The 
reverse transcription reaction was performed in a total volume of 20µl with 0.25 µg/µl total RNA, 
1µmol/µl polyT primer, 10µmol/µl random hexamers, 0.5 mM dNTP’s, 0.5 U/µl RNAse Inhibitor and 0.2 
U/µl Omniscript reverse transcriptase. The reaction mixture was incubated for 1h at 37°C in a DNA 
Engine Tetrad® thermocycler and the generated cDNA was used for subsequent amplification without 
previous clean up or quantification. 
3.3.2. Real time PCR for quantitative expression measurement 
Primer assays were manually designed for quantitative amplification of the generated cDNA. Each 
assay contained primers located on consecutive exons and spanning a large intron to ensure 
amplification of only cDNA and not genomic DNA contaminants. The used primer sequences are given 
in Table 3 (chapter 7.3, appendix). 
The real time PCR assays were performed by means of the SYBR Green PCR master mix chemistry 
in an ABI Prism 7900HT Sequence detection system. 
The total reaction volume was 15µl comprising 7.5µl of the SYBR Green PCR master mix, 1.5µl of the 
individual cDNA dilution (1:100) and a final concentration of 0.4µM primers. The temperature profile 
was the following: initial activation of the polymerase at 96°C for 10 minutes followed by 40 cycles w ith 
the profile: 95°C for 15 seconds, 60°C for 1 minute , 72°C for 30 seconds. Fluorescence intensities 
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were measured in each cycle during the annealing and extention step (from 60°C – 70°C). Analysis of 
the real-time PCR was performed by means of the ABI SDS 2.2 software. 
Relative mRNA expression was calculated as described by Muller et al. (134) using the glycerol 
aldehyd-3-phosphate dehydrogenase gene (GAPDH) amplification as reference for normalization. 
Expression of each gene was calculated by averaging the normalized expression values of three 
independent measurements. Mean values were plotted against averaged methylation levels for regions 
with significant differential methylation between the analyzed cell lines (Figure 4-15). 
The expression quantification as determined by the Q-gene software developed by Muller et al. is 
described in the chapter 3.5. 
3.4. Chromatin immunoprecipitation 
Sorted IL-10-secreting and nonsecreting cells were fixed with 1% formaldehyde for 10 min at room 
temperature. The fixation was stopped with 0.125 M glycine. The chromatin was sheared to obtain 
fragment lengths of approximately 200–1000 bp by sonication with five pulses of 10 seconds at 30% 
power on a Bandelin sonicator. The chromatin was incubated with antibodies directed against 
hyperacetylated histone H3 (H3Ac) or Lysine 4 trimethylated histone H3 (H3K3me3) overnight, 
followed by incubation with ProteinA-MicroBeads for 2-hours. Washing steps were performed on 
 
 
columns with high salt, low salt, LiCl, and TE buffer sequentially. Chromatin precipitate was eluted with 
1%SDS, 0.1M NaHCO3. Crosslinks were reversed by incubation at 65 °C f or 4-hour in the presence of 
0.2 M NaCl, and the DNA was purified with NucleoSpin Extract II. The amount of immunoprecipitated 
DNA was determined by real time PCR with LightCycler instrument 2.0 using FASTStart SYBR Green 
Master Mix. The relative amount of DNA was calculated with the formula 2(crossing point input - crossing point input). 
The primer sequences used for the amplification of the crosslinked DNA are given in Table 4 (chapter 
7.4, appendix). 
3.5. Statistical methods 
3.5.1. Kruskal Wallis test, Wilcoxon test and Bonferroni correction 
For statistical analysis, methylation levels of adjacent CpGs within a region were averaged for each 
individual sample.  
For more than two groups comparisons (as applied in chapter 4.2.1), the resulting means were tested 
for significance (< 0.05) by using the non-parametrical Kruskal Wallis rank sum test. This test allows 
the analysis of variance (comparison of means) between more than two groups, without assuming a 
normal population. Each averaged methylation was considered an independent measurement. Due to 
the low sample numbers in the single tested groups, the resulting p – values were left uncorrected. The 
significance level applied was 0.05. 
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For two group comparisons, as applied in chapter 4.3.3, the averaged methylation levels between the 
two cancer entities and normal lymph node DNA were compared using the Wilcoxon rank statistics 
followed by Bonferroni correction. The Wilcoxon test is too a rank sum test for comparison of means 
between two independent sample groups which does not require information about the data 
distribution.  
The Bonferroni correction is a conservative adjustment of the significance level to account for multiple 
comparisons when more than one hypothesis is tested on the same data. In order to avoid falsely 
positive tested hypothesis, the p – value is multiplied with the number of tested hypotheses thus 
increasing its individual value for each hypothesis.  
If not otherwise specified, a Students t-test was used to interrogate statistical significance. All reported 
p–values are twosided and all confidence intervals are quoted at the 95% level. 
3.5.2. Box-whisker plots  
In order to visualize different types of populations in one plot, averaged methylation data for different 
biological questions were displayed as box whisker plots.  
A given dataset is segmented into two measures of dispersion (quartiles), a measure of central location 
(median), the maximal value and the lowest data value. These measures are plotted such, that the 
lower whisker represents the lowest observation followed by the data belonging to the lower quartile 
(Q1), the median and the upper quartile (Q3) all being depicted in the box. Thus, the box represents 
50% of the data. The largest observation is shown graphically in the upper whisker. In addition, the 
boxplots indicates which measurements are considered unusual (outliers) by the dots below the lower 
whisker or above the upper whisker. The box plots in this study were generated by the software 
Microsoft Excel 2003 software. 
3.5.3. Q-gene software for mRNA analysis 
The Q-gene software was used to calculated mean normalized expression of the transcription factor 
genes in the cell lines (Figure 4-15) and was developed by Muller et al. as a Microsoft Excel based 
software application(134). The software requires three independent measurements (raw c0t values) for 
each mRNA and from the selected reference gene. It then calculates the mean normalized expression 
by averaging the three independently calculated normalized expressions stemming from the triplicate 
measurements. Thereby, the PCR efficiencies of the reference gene and the target gene are not 
considered equal. The standard error is calculated by means of the Gaussian differential equation and 
is included in the graphical output. 
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4. Results 
4.1. Epigenetic control in the immune system: DNA 
methylation of cytokine and transcription factor genes 
in T-helper cell subsets 
4.1.1. Isolation of CD4+ memory cells secreting IL-10 and / or IFN-γ 
To isolate ex vivo different human T-helper (Th) cell subsets secreting IL-10 or IFN-γ or both, CD4+ 
lymphocytes from the peripheral blood of 30 individuals were isolated as described in the methods 
section (chapter 0). A double cytokine secretion assay was performed to select for cells expressing 
IFN-γ and / or IL-10. After stimulating CD4+ T-cells with P/I, following intracellular cytokine productions 
were induced and the different cell types could be isolated: IL-10+IFN-γ- (1-5% of total cells, IL-10 
positive), IL-10+IFN-γ+ (0.6-3% of total cells, Double positive), IL-10-IFN-γ+ (5-15% of total cells, IFN-γ 
positive) and IL-10-IFN-γ- (80-90% of total cells, Double negative) (Figure 4-1 A), shown for one 
randomly selected donor). Each individual cell type was FACS sorted to a purity > 95% (Figure 4-1 B). 
As they are characterized by expression of the CD45RO isoform, IL-10 positive, IFN-γ positive and the 
Double positive cells resembled antigen-experienced memory Th-cells properties. The double negative 
cells are CD4+ naive-like cells, expressing the CD45RA isoform. In order to confirm the supposed 
cytokine secretion pattern of the isolated Th-cell subsets, the purified cells were cultured for 48-hr or 
72-hr and supernatants were analyzed for various cytokine productions (IL-4, IL-5, IL-10, IFN-γ and 
TNF-  ) by a cytokine bead array (CBA). IL-10+IFN-γ- Th-cells produced only IL-10 but no IFN-γ, while 
IL-10-IFN-γ+ Th-cells produced only IFN-γ, but no IL-10. As expected, Treg1-like IL-10+IFN-γ+ Th-cells 
secreted both cytokines, whereas IL-10-IFN-γ- Th-cells secreted neither one. All cells expressed the T-
cell differentiation and proliferation factor IL-2 (Figure 4-1 C). The other cytokines, IL-4, IL-5 and TNF-   
are not expressed by any of the purified cell types excluding thus the co-purification of Th2 IL-10 
secreting cells. 
For control purposes, human Th1 and Th2 cell lines obtained from a collaborator group were included 
in the study and DNA methylation analysis was performed at the same loci as analyzed in the ex vivo 
cells. 
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Figure 4-1 (A) Induction and analysis of CD4+ Th-cell subsets. The following Th-cell 
subsets were identified: IL-10+IFNγ-, IL-10+IFNγ+, and IL-10-IFNγ+ and IL-10-IFNγ-. (B) Purity analysis 
of CD4+ Th-cell subsets. The induced Th-cell subsets were sorted by a FACSDiva. A small fraction of 
each sorted subset was reanalyzed for purity on a FACScalibur. (C) Distinct cytokine profiles of CD4+ 
Th-cell subsets. Equal amounts of cells from each subset were cultured 48- or 72-hr. Supernatants were 
assessed for IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ (from top to bottom) by a CBA and results were 
analyzed on a FACScalibur. 
 
mRNA expression of IL-10, IFN-γ, GATA3 and TBX21 
Subsequently, quantitative real-time PCR analysis was performed on the four cell types from five 
randomly selected donors to assess mRNA expression of IL-10 and IFN-γ and to evaluate expression 
levels of transcription factors that have been associated with the regulation of IL-10 and IFN-γ such as 
GATA-3 (135), (136) and TBX21 (137). Abundant amounts of IL-10 mRNA were measured only in IL-
10 secreting subsets, IL-10+IFN-γ- and IL-10+IFN-γ+ Th-cells. GATA-3 mRNA expression was 
significantly higher in IL-10+IFN-γ- Th-cells in comparison to IL-10+IFN-γ+ Th-cells. This is in 
agreement with recently published data where the Th2 key regulator GATA-3 was identified to directly 
influence IL-10 expression by chromatin remodelling at the IL-10 gene locus (138). As expected, IFN-γ 
and increased TBX21 mRNA expression levels were restricted to IFN-γ-secreting Th-cells, except for 
one sample with lower expression in the IL-10+IFN-γ+ Th-cells in comparison to the other four donors 
(Figure 4-2).  
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Figure 4-2 mRNA expression of IL-10, IFN-γ and the transcription factors GATA-3 and 
TBX21 in the isolated Th-cell subsets IL-10+/IFN-γ-, IL-10+/IFN-γ+, IL-10-/IFN-γ+ and IL-10-/IFN-γ-. 
Expression was quantified by real-time PCR. The data shown is derived from five independent biological 
samples. 
4.1.2. DNA methylation profiles of IL4, IL13, GATA3 and TBX21 in 
CD4+ memory cells 
In order to avoid confounding effects such as age, gender or other yet unknown differences and to 
enable work with the small cell numbers obtained for the IL-10+IFN-γ+ cell type, pools of 10 donors 
were formed resulting in a total of 12 samples (three independent biologic samples for each of the four 
subsets). Age and gender of the obtained donors, as well as the individual pool composition are 
summarized in Table 3 in the appendix. These samples were used for DNA extraction, bisulfitation, 
PCR amplification and direct bisulfite sequencing. As a control, clonally expanded human Th1 and Th2 
IL-10+ and IL-10- cells were used and DNA methylation profiles were determined as well. 
For all genes, regions encompassing several kilobases upstream of the TSS were selected for analysis 
with a focus on evolutionary inter-species conserved non-coding regions (CNS) containing putative 
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regulatory sequences (139). The species used for alignment comparison were mouse and rat. Both 
analyzed transcription factors, GATA-3 and TBX21 have CpG islands located at the 5’ end of the gene 
locus in the promoter region. None of the four analyzed cytokine genes (IL4, IL13, IL10 and IFNγ) 
displayed CpG dense regions or annotated CpG islands in their promoters. 
The methylation profiles for the cytokine genes IL4 and IL13 and the transcription factor genes GATA3 
and TBX21 are shown in Figure 4-3. 
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Figure 4-3 Genomic organisation and DNA methylation profiles of the gene loci IL4, 
IL13 (A), GATA3 (B) and TBX21 (C) in four distinct T cell types: IL-10-/IFN-γ- naive cells, IFN-γ+ Th1 like 
cells, IL-10+/IFN-γ+ Treg like cells and IL-10+ cells. Three independent samples, each consisting of 
pooled cells of the same type from 10 healthy donors were analyzed. The analyzed genomic regions are 
depicted in dark grey bars below the gene location. Green boxes represent conserved non-coding 
sequences (CNS) as determined by interspecies comparison between human, mouse and rat genome 
(Ensembl). CpG islands, as determined by the Ensemble (release 44) are shown as light grey bars. 
Black boxes represent exons; non–filled boxes stand for untranslated regions. 
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The Th2 specific cytokine genes IL4, IL5 and IL13 are clustered in a 160 kb region on the short arm of 
human chromosome 5 (Figure 4-3 A, IL5 locus not shown). The expression of IL-4 and IL-13 was 
shown to be coordinatively regulated in Th2 cells by a locus control region (LCR) located downstream 
of the IL13 gene (Figure 4-3 A, red arrow) (140). A LCR is a sequence element outside of coding 
regions that confers tissue specific high level expression of the linked genes, presumably by overriding 
suppressive effects of the flanking DNA sequences (141). 
Analysis of the IL4 and IL13 loci revealed differential methylation between IL-10-/IFN-γ- naive cells on 
the one side and IFN-γ+, IL-10+/IFN-γ+ and IL-10+ cells on the other side within the LCR (Figure 4-3 A, 
region 3). While naive cells display levels of >90% methylation for all CpGs in the region, the remaining 
three cell types have significantly decreased levels of ~50% (p<0.004), with exception of two CpGs 
located in the middle of the analyzed fragment. Similar patterns were observed for several regions 
located intragenic of IL-4 (Figure 4-3 A, region 4-8). However, for regions 6, 7 and 8, IL-10+ cells tend 
to have a higher degree of methylation when compared to IFN-γ+ and IL-10+/IFN-γ+ cells. 
A methylation level of 50% is indicative of allele specific methylation, whereby one allele is silenced by 
a 100% methylated locus and the other shows hypomethylation and permissive chromatin state. The 
methylation data presented here is in line with the previous finding that both genes, IL4 and IL13, are 
expressed preferentially from one chromosome rather than at random (142). 
CpGs located approximately 1.5 kb upstream of the IL13 gene are hypomethylated in all four analyzed 
cell types (<20%) while the proximal 5’ promoter region and parts of exon 1 display high levels of 
methylation, greater than 80% (Figure 4-3 A). Two CpGs within this latter region are demethylated in 
the double positive IL-10+/IFN-γ+ cells. All downstream intragenic regions of the IL4 gene (regions 9–
15) are strongly methylated in all analyzed cell types. The three CpGs located downstream at region 16 
belong to a conserved element and are unmethylated in all four cell types. 
GATA-3 and TBX21 are two transcriptional regulators shown to direct naive T-cell differentiation 
towards Th2 and Th1 effector cells respectively. 
The GATA3 gene promoter consists of a 5.0 kb large CpG island comprising a number of conserved 
DNA streches consistently downmethylated in all analyzed cell types (Figure 4-3 B, regions 3-7). This 
finding is in agreement with the general notion, that CpG island methylation is very low in normal cells. 
None of the analyzed regions display differential methylation between any of the different cell types 
although GATA-3 was shown to be differentially expressed in the analyzed cell types (Figure 4-2) 
suggesting no role for DNA methylation in the expression regulation of this gene. 
Similar to the methylation levels detected in the CpG island of the GATA3 gene, the CpG island of the 
TBX21 is unmethylated in all analyzed cell types (Figure 4-3 C, region 1). Interestingly, the intragenic 
regions 2 and 3, both spanning conserved sequence elements display lower levels of methylation in 
IFN-γ+ cells as compared to IFN-γ- cells (Figure 4-3 C, regions 2-3). Consistently, IFN-γ+ cells were 
shown to have lower levels of TBX21 expression (Figure 4-2). As TBX21 was shown to be directly 
involved in the regulation of the IFNγ gene expression and to be a key transcription factor in Th1 cells 
(137), (143) the presented data suggests a role for DNA methylation in the regulation of the TBX21 
transcription. 
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4.1.3. Epigenetic modifications of the IL-10 locus 
4.1.3.1. IL-10 DNA methylation profiling in CD4+ memory cells  
Seven amplificates have been designed within the IL-10 gene encompassing 48 CpGs. Region 1, 
located approximately 9.0 kb upstream of the annotated TSS and covering two CpGs is followed by 
regions with slightly higher CpG density upstream of the TSS. Region 5, located in the proximal 
promoter, contains six CpGs. Regions 6 and 7 are located within the gene body in the introns 1 and 4 
respectively (Figure 4-4 A). Alignments between the human, mouse, and rat IL-10 locus were 
performed and the extent of DNA sequence homology was computed with the web-based program 
VISTA (http://genome.lbl.gov/vista/index.shtml). Regions outside annotated exons with a length of at 
least 100bp that show sequence identity greater than 75% were considered conserved non coding 
(CNS) regions with putative regulatory functions. The criteria are fulfilled by regions 5 and 7 (Figure 4-4 
A). The methylation analysis was performed in the previously isolated CD4+ memory cell subsets and 
in IL-10+ and IL-10- T-helper (Th) cell clones of both types, Th1 and Th2. 
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Figure 4-4 (A) Genomic organisation of the human IL10 gene with interspecies 
sequence alignment between human, mouse and rat. Genomic regions with sequence similarity greater 
than 50% over at least 100bp are shown in the histogram plot. (B) DNA methylation profiles of the IL10 
locus in CD4+ Th-lymphocytes. The methylation heat charts represent triplicate measurements of three 
samples, each resulting from pooling the genomic DNA of of ten individuals. (C) DNA methylation 
profiles at selected regions in the IL10 locus in IL-10+ and IL-10- Th cell clones. 
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With the exception of two 3’ CpGs of region 5, no methylation pattern specific for IL-10-secreting Th-
cells was found as compared to IL-10 non-secreting Th-cells. Two CpGs of region 1, located 9.1 kb 
upstream of the transcriptional start site, showed low levels of methylation in both IL-10+ and IL-10- 
Th-cells. CpGs of regions 2 and 3 (5.5 and 5.0 kb upstream) were almost fully methylated in all cell 
subsets (Figure 4-4 B). CpGs of region 4 (2.5 kb upstream) and 6 (intron 1) displayed alternating 
patterns of methylation, without an explicit preference assignable to a certain Th-cell subset (Figure 4-4 
B). The conserved region 7 (intron 4) displayed hypermethylation of the first three CpGs in the double 
negative cells for all samples, while the single positive IFN-γ+ and IL-10+ cells display 50% 
methylation. Exceptions are two pools within the double positive cells (pool2 and pool3) with relatively 
low level of methylation for this specific CpGs. As pool 1 does not display the same pattern and this 
methylation pattern does not correlate to IL-10 expression, these three CpGs were not investigated 
further. The 3’ CpGs of region 7 show a low level of methylation throughout all Th-cell subsets 
analyzed (Figure 4-4 B). 
The human IL-10+ and IL-10- Th cell clones displayed similar methylation profiles as described in the 
ex vivo T-cells for all analyzed regions (Figure 4-4 C). Again, with the exception of the most 3’ CpG of 
region 5 (Figure 4-4 C), no methylation differences were observed between IL-10+ and IL-10- cells. 
The adjacent CpG. However. is hypermethylated in both IL-10+ and IL-10- Th cell clones (Figure 4-4 
C). In addition, the aforementioned 3’ CpGs of region 5 (proximal promoter) are slightly demethylated 
in both IL-10+ Th1 and Th2 cell clones as compared to IL-10- Th1 and Th2 cell clones.  
The CpG at position –161 (relative to the TSS) has an overall level of 100% methylation in IL-10- cells 
(averaged over the six pools of IL-10- cells), while the IL-10+ cells have only 75% methylation (Figure 
4-4 B). Even more specifically, the CpG located 75bp downstream at position –86 is 85% methylated in 
IL-10- cells and approximately 25% in the IL-10+ cells (Figure 4-4 B).  
These two CpGs are of special interest since they are located in a region of high sequence similarity to 
the mouse genome where homologue CpGs have been shown to be specifically downmethylated in the 
mouse Th2 cell line D10 in contrast to the Th1 cell line D5. In addition, these CpGs are located in 
DNAseI hypersensitivity regions in the mouse. Hypersensitivity regions are usually correlated to an 
open, permissive chromatin status (99). However, no such data has yet been reported for human ex 
vivo T-helper cells. 
4.1.3.2. High resolution methylation analysis of the IL-10 region 5 
To analyse the methylation status at the 5’ CpGs of region 5 at a higher resolution, sequencing of 
clones derived from non-pooled, randomly selected individual DNA samples was performed. For each 
individual cell type, two donors were selected and their bisulfited DNA was amplified specifically at the 
IL10 region 5. The resulting PCR products were cloned into a plasmid and transfected into E. coli. 
Isolated bacterial clones carry thus a single version of a PCR strand with binary methylation 
information. A total number of 138 clones distributed on the four cell subsets were analyzed by 
sequencing. Table 5 (appendix) summarizes the number of clones for each single cell type together 
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with age and gender of the selected donors. Wilcoxon rank sum statistics followed by Bonferroni 
correction was performed to assess the statistical significance of the differential methylation at each 
single CpG position. The CpGs at positions -86 and -161 strongly differentiate between IL-10+ and IL-
10- cells (p< 0.26x10-10 and p< 0.94x10-4). While IL-10+ cells show a clear tendency to be 
demethylated at these CpG positions, IL-10- cells are mostly upmethylated suggesting thus a less 
permissive chromatin conformation in the specific region (Figure 4-5). Thus, the low methylation status 
at these three CpG positions in IL-10+ cells correlates with the expression of the gene. Although other 
CpGs in region, located upstream of the TSS and downstream of the CpG at position -349, show 
demethylation in some of the clones, they do not reach statistical significance. 
No significant difference was detected between the two distinct IL-10+ cell types (double positive and 
single positive) as well as between the two IL-10- cell types (double negative and single negative) at 
this specific region 5 (Figure 4-5). 
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Figure 4-5 Bisulfite clone sequencing of the IL10 region 5. Up to 38 clones derived from 
the PCR products of two individuals were sequenced for each cell type. The relative position of each 
analyzed CpG within the region is given on top of the chart. 
4.1.3.3. Histone acetylation and histone methylation at the IL-10 locus 
To gain more insights into the epigenetic status of the IL-10 locus in IL-10 expressing Th cells, a 
chromatin immunoprecipitation (ChIP) assay was performed to analyse the histone modifications. 
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Certain chemical modifications of the local histones like acetylation of histone 3 or trimethylation at the 
lysine-4 position of histone 3 are associated with an open chromatin status thus allowing the binding of 
transcription factors and other transcriptional enhancers as reviewed in (144), (145). 
IL-10+ and IL-10- CD4+ / CD45RO+ cells were isolated from two different donors and the ChIP assay 
was performed as described in chapter 3.4. The genomic regions 1, 2, 4 and 5 (Figure 4-4 A) were 
amplified by real time PCR after immunoprecipitation with the respective antibody and the amount of 
amplified DNA was normalized to the previously measured input DNA. 
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Figure 4-6 Histone acetylation (H3Ac) and histone trimethylation (H3K4me3) at 
indicated regions (x-axis) in the putative IL10 gene promoter of ex vivo purified IL-10+ and IL-10- Th-
cells. Immunoprecipitated DNA was quantified by real-time PCR and normalized to input DNA amounts 
(y-axis). 
 
High levels of histone 3 acetylation and methylation were observed in IL-10+ cells from donor 2 within 
the region 5 (Figure 4-6). Less prominent, but with the same tendency is the data for region 5 in IL-10+ 
cells from donor 1. The regions 1, 2 and 4 deliver conflicting data between the individual donors in the 
histone trimethylation experiment. While IL-10+ cells of donor 2 are strongly methylated at the 
respective histones when compared to IL-10- cells, the difference between the two cell types in donor 1 
is not statistically relevant (Figure 4-6). Also, the differences between donor 1 and donor 2 in 
acetylation at the regions 1, 2 and 4 are insignificant (Figure 4-6). 
Since the two differentially methylated CpGs between IL-10+ and IL-10- cells are located in region 5, 
the observed histone acetylation and trimethylation marks are strengthening the assumption that this 
promoter region harbors regulatory functions for the expression of the downstream IL10 gene. 
4.1.3.4. Loss of IL10 expression after rounds of in vitro cultivation 
“Epigenetic memory” is defined as the inherited epigenetic status of a specialized cell type which is 
stably maintained after rounds of proliferation and harbours the information for the specific gene activity 
in the cell (35). To analyse wheather the demethylated CpGs at position -86 and -161 relative to the 
TSS and the modified histones in IL-10+ cells harbor the epigenetic memory for IL-10 expression, IL-
10+, IL-10+/IFN-γ+ and IL-10-/IFN-γ+ cells were isolated from PBMC fractions of healthy donors and 
cultured in vitro for a period of two weeks. The expression of IL-10 and IFN-γ was monitored by 
intracellular staining and FACS analysis and the DNA methylation was measured after the expansion 
Results  Page 53 
period in both IL-10+ and IL-10- cell fraction. Figure 4-7 shows the frequency of cells with IL-10 
expression after the in vitro cultivation period. 
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Figure 4-7 Loss of IL-10 expression after in vitro cultivation and re-isolation. Ex vivo 
isolated IL-10+/IFNγ-, IL-10+/IFNγ+ and IL-10-/IFNγ+ cell subsets were expanded for one week under 
neutral (rIL-7 plus rIL-15) conditions. After one week, a second cytokine secretion assay for IL-10 and 
IFNγ was performed and IL-10+/IFNγ- cells were re-isolated out of the first round sorted IL-10+/IFN-γ- 
cells. Re-expression of IL-10 and IFN-γ was assessed by intracellular staining following P/I restimulation 
for all subsets after one week and after another week of culture for re-isolated IL-10+/IFNγ- cells. 
 
While more than 95% of the IL-10-/IFN-γ+ cells maintain the ability to produce IFNγ upon culture in vitro 
(Figure 4-7), less than 13% IL-10+ cells produce IL-10 after cultivation under the same conditions in 
the same period. After one week of in vitro cultivation, remaining IL-10 producing cells were re-isolated 
and kept under the same conditions for additional seven days to monitor the IL-10 expression 
maintenance. Similar to the first cultivation round, more than 90% of the cells had lost the ability to 
express IL-10 (Figure 4-7). To verify if de novo DNA methylation occurs at the CpG loci -86 and -161 
during in vitro cultivation, methylation was measured within region 5 and region 3 as reference (Figure 
4-8) in both cell types, IL-10+ and IL-10-. 
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Figure 4-8 DNA methylation of the regions 3 and 5 after two weeks of in vitro cultivation 
of ex vivo isolated IL-10+ cells. The upper raw (I) displays the methylation pattern of cells which maintain 
the ability to produce IL-10, while the lower line (II) shows the methylation pattern of cells that have 
abandoned IL-10 production. 
 
The previously demethylated CpGs -86 and -161 in ex vivo IL-10 producing cells remain demethylated 
in culture regardless of the IL-10 expression pattern, suggesting that the two differentially methylated 
CpGs do not harbor the epigenetic memory to maintain IL-10 production when cultured under 
conditions sufficient for expansion. Thus, IL-10 expression might not be part of a programmed cell 
memory but its expression is rather dependent on extracellular stimuli. 
4.1.4. DNA methylation at the IFNγ locus 
4.1.4.1. DNA methylation profiling of the IFNγ gene in CD4+ memory cells 
For the IFNγ gene, amplicons were designed in five selected regions covering a total of 28 CpGs and 
spanning a stretch of 6.3 kb. Region 1 is positioned within a previously described IFN-γ regulatory 
element ~4.0 kb upstream of the annotated TSS. This element was discovered by interspecies 
alignment as being located within a highly conserved non coding sequence (CNS) which is associated 
with low methylation levels and DNAseI hypersensitivity in IFN-γ expressing T-cells in mouse (102). 
Regions 2 and 3 span a conserved non-coding element, in the proximal promoter (Figure 4-9). Regions 
3, 4 and 5 span the exons 1 and 3 respectively (Figure 4-9). 
The methylation analysis was performed on the DNA of the pooled samples as described in chapter 
4.1.3. A very pronounced pattern of differential methylation was observed for all of the analyzed 
regions. IFN-γ expressing cells tend to have extremely low methylation levels (<10%) at all analyzed 
CpGs, while IFN-γ negative cells display methylation levels higher than 80% at the same CpG positions 
(Figure 4-9). The results are in agreement with recently published data showing that hypomethylation 
of the IFNγ promoter is correlated with the cells potential to express IFN-γ (55). 
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Figure 4-9 Genomic organisation of the human IFNγ  gene and DNA methylation 
profiles of the IFNγ  locus in CD4+ T-helper cells. Heat charts display the methylation levels of each 
individual CpG from triplicate measurements of the three independent pooled samples. CNS: conserved 
non-coding sequence. 
4.1.4.2. Demethylation dynamics at the IFNγ locus after six days of in vitro 
cultivation 
Based on the results obtained in the ex vivo cells, where it was shown that IFN-γ- phenotypes are 
hypermethylated in the promoter and several intragenic CpGs, in vitro cultivation of naive T – cells 
(CD4+CD45RA) was performed under different stimulation conditions that determine cell differentiation 
towards Th1-like cells. The aim of the experiment was to monitor the local DNA methylation status 
upon which IFN-γ expression is induced and to observe the interdependence between methylation and 
expression. Additionally, by using three different stimulation conditions, it was tested which in vitro 
stimulus is capable of inducing the lowest level of methylation in the same period of time thus 
resembling most closely the in vivo cell differentiation conditions. The applied stimuli were the 
following: stimulus I: anti-CD3/anti-CD28, rIL12 and aIL4, stimulus II: anti-CD3/anti-CD28, rIL12, IFN-γ 
and anti-IL4 and stimulus III: allogeneic dendritic cells (allo DC). At day six of cultivation, the cells were 
harvested and FACS-separated according to their IFN-γ expression status. 
After sorting, the genomic DNA was extracted and used for DNA methylation measurement at the IFNγ 
locus. Every cultivation experiment was performed in duplicates. All five regions shown in Figure 4-9 
were analyzed by bisulfite sequencing in triplicate experiments. The DNA methylation rates for 
individual CpGs were averaged (mean) for each of the five analyzed regions and the methylation 
measurements were plotted for each region (Figure 4-10). 
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Figure 4-10 Averaged methylation levels of IFN-γ- and IFN-γ+ cells after six days of  
in vitro cultivation towards Th1 differentiation under different stimulation conditions. 
 
Regions 1, 2 and 3 showed significantly decreased methylation levels between IFN-γ– and IFN-γ+ cells 
for all three differentiation conditions (p < 0.008, 0.001 and 0.0002 for the stimuli I, II and III 
respectively). While IFN-γ- cells are hypermethylated like their naive precursors, the IFN-γ+ are slightly 
less methylated. However, while external stimuli I and II do not differ strongly in their influence of the 
local methylation and induce IFN-γ expression after relatively low methylation decrease (50% – 75%), 
the allogeneic dendritic cells induce a significantly stronger decrease in methylation within both, IFN-γ- 
and IFN-γ+ cells. 
The interdependence between methylation and expression, however, does not become clear after this 
experiment. While average methylation levels of 60% - 75% still allow IFN-γ expression (regions 1, 2 
and 3 in IFN-γ+ cells), an overall of 50% methylation within the IFN-γ– cells generated by stimulus III 
does not allow expression yet. This can be explained in part by the role of individual CpGs within the 
regions of interest, especially those located on binding sites of TBX21 and CREB transcriptional 
regulators (54), (55). It is difficult to describe CpGs individually by the data analysis approach selected 
here. Instead, they need to be analyzed by a quantitative methods like methylation sensitive restriction 
nucleases combined with real – time PCR techniques. 
In addition, it was recently described (146) that the hypermethylated IFN-γ promoter can be 
transactivated upon strong extracellular signalling followed by induction of IFN-γ expression which 
would explain the high methylation levels in IFN-γ+ cells obtained after treatment with the stimuli I and 
II. 
The boxplots in Figure 4-11 summarize the methylation results by averaging the three significant 
regions (1, 2 and 3) for the individual stimuli. The mean variation (box height) of the methylation in IFN-
γ- cells is less than that in the IFN-γ+ cells, suggesting that the IFN-γ- cells are a more homogenous 
population of cells and underlining the effect of methylation states of individual key CpGs for 
expression induction. 
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Figure 4-11 Box plots of averaged DNA methylation for all analyzed CpGs within regions 
1, 2 and 3 
 
However, despite the relatively low methylation levels obtained with the stimulus III, the methylation 
levels measured in vivo could not be reached under any of the conditions tested in vitro. In addition, 
while Th1 cells show in vivo hypomethylation within the entire IFN-γ locus (promoter and intragenic 
regions), regions 4 and 5 remain largely hypermethylated suggesting that the cells obtained after six 
days of cultivation in vitro (approximately four rounds of proliferation) do not resemble native Th1 cell 
methylation patterns at the IFNγ locus. 
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4.2. Epigenetic control in the immune system: DNA 
methylation of transcription factors in hematopoietic 
development 
4.2.1. Methylation profiling of 13 transcription factor genes in 
consecutive stages of normal T- and B-cell development 
For DNA methylation profiling, 13 transcription factor genes (Table 2) previously shown to be key 
regulators in adult lymphocyte development and lineage commitment were chosen (147), (148). Figure 
2-5 shows schematically the expression of each selected TF in distinct lineages and / or at specific 
developmental stages (149), (112), (150), (151). 
For each gene, several putative regulatory regions were analyzed (Figure 4-12) and the respective 
DNA methylation profiles were determined. These regions were selected by two different approaches. 
Firstly, for each gene, CpG-dense regions or CpG islands located within the 5’ untranslated regions 
(UTR) were selected. Secondly, we identified highly conserved non-coding elements (CNS) containing 
isolated CpGs by interspecies comparison. This strategy has successfully been used before to identify 
regulatory elements for other genes and model organisms (139), (152). In order to identify non-
promoter associated regions of differential methylation, some of the amplicons were located up to 7.0 
kb upstream and 5.0 kb downstream of the annotated transcription start site (TSS).  
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Figure 4-12  Localization of regions (black bars) profiled for DNA methylation within the 
genomic context for all selected genes. Non-coding exons are shown as empty boxes; coding exons are 
depicted as solid boxes. A scale bar (1.0 kb) for each gene and CpG islands (CGIs) as annotated by 
Ensembl (NCBI 36) are shown. 
 
Methylation comparisons were performed between cell types representing consecutive stages of the 
human adult hematopoietic cascade (Figure 2-5): (1) bone marrow derived hematopoietic progenitor 
cells, (n=3), (2) CD4+ naive cells (n=3), (3) CD8+ naive cells (n=2), (4) CD19+ naive B-cells (n=2), (5) 
CD4+ (IFN-  +) memory cells (n=3), (6) CD8+ memory cells (n=4) and (7) CD19+ memory B-cells 
(n=2). 
Significant methylation differences were detected between the seven cell types in specific regions of 
SPI1, GATA3, TCF-7, Etv5, c-MAF and TBX21. For the remaining genes, FOG1, Hlx, Eomes, Notch1, 
Th-POK, STAT1, and STAT6, no differential methylation could be identified in any of the examined 
regions. Figure 4-13 A shows the level of differential methylation for each individual CpG in the 
sequence of the selected regions. Figure 4-13 B shows the average methylation of genes that 
displayed no differential methylation. The methylation heat charts in Figure 4-13 B are consist of 
averaged methylation of individual CpGs located within the analysed genomic region. This is possible, 
when co-methylation, or identical levels of methylation are observed between adjacent CpGs. 
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Figure 4-13  (A) CpG wise DNA methylation profiles of selected transcription factors in 
progenitor, T- and B-cells of different developmental stages. Selected differentially methylated regions 
are displayed for each gene within the analyzed cell types. (B) Averaged methylation levels of 
transcription factor gene regions that are not differentially methylated within the analyzed lineages and 
developmental stages. The gene names and the displayed regions are indicated. The colour code is 
given below. HPC: hematopoietic progenitor cells. 
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Within the SPI1 gene locus, all 22 analyzed CpGs located within the 5’ UTR, exon1 and intron1 were 
unmethylated (Figure 4-12 and Figure 4-13 A, average methylation level< 5%) in the progenitor cells 
(CD34+), naive and mature B cells. In contrast, the same region showed increased methylation  
(> 60%, p   0.001) in all naive and memory cells of the T-cell lineage, indicating that this gene is 
specifically methylated in this lineage. More specifically, the Th2 dominant transcription factor GATA3 
(147) displayed reduced methylation levels within the analyzed region 2 (Figure 4-12 and Figure 4-13 
A, p   0.02) only in naive and memory CD4+ lymphocytes but not in CD34+ cells, CD8+ lymphocytes 
and B-cells. 
Regions within TCF7, Etv5, c-MAF and TBX21 displayed differential methylation patterns as well 
Figure 4-13. In contrast to SPI1 and GATA3, the methylation of these genes was dependent on the 
differentiation state (naive versus memory) as opposed to the cell type itself (i.e. B-cells versus T-
cells). For TCF7, a region of 630 bp located about 0.7 kb upstream of the TSS (regions 1 and 2, Figure 
4-12) was consistently higher methylated (>60%, p   0.001) in all B- and T- memory cells compared to 
progenitor cells and naive B- and T-lymphocytes (Figure 4-13 A). Within the memory lymphocyte 
group, a gradual, lineage dependent increase in methylation was detected, with CD8+ memory 
lymphocytes showing the highest methylation level and an increase in DNA methylation towards more 
downstream regions for this cell type (region 3, Figure 4-12 and Figure 4-13 A). A similar, but less 
pronounced increase of DNA methylation in memory lymphocytes was observed for the Etv5 gene (p   
0.002), in a region located approximately 2.0 kb upstream of the cognate TSS (region 1, Figure 4-12). 
However, consistent hypermethylation in memory cells is not a general phenomenon, as decrease of 
DNA methylation in c-MAF (p   0.001, region 3 and 4) and TBX21 (p   0.002, region 1) in the memory 
lymphocytes as compared to the naive lymphocytes was measured. For c-MAF, the region of 
differential methylation was spatially limited: homogenous hypermethylation was measured in regions 
further upstream (region 1 and to some extend region 2). The CpGs of the annotated CpG island in the 
5’-UTR of c-MAF (region 5) were unmethylated throughout lymphopoiesis. Interestingly, the T-helper1 
specific transcription factor TBX21 displayed differential methylation within the analyzed region located 
in intron 1 but not in the putative promoter region (Figure 4-3 C). 
Figure 4-13 B displays averaged methylation rates of analyzed regions of genes that were not 
differentially methylated such as FOG-1, Notch-1, Hlx1, Eomes, Th-POK and STAT1. These gene 
regions were either unmethylated or displayed rather low methylation (<40%) with the exception of an 
intragenic region of STAT6 that was homogenously hypermethylated (Figure 4-13 B). A number of the 
analyzed genes have a CpG island (CGI) within their 5’-UTR which were all unmethylated, consistent 
with the notion that the majority of CGIs in the human genome are unmethylated (153). 
4.2.2. Methylation - expression correlation of TF genes in cell lines 
A number of genes, including tumor suppressor genes, are regulated via DNA methylation in the 
promoter and other regulatory regions (6). In some cases, promoter hypermethylation leads to gene 
silencing, while unmethylated promoters are associated with transcription of the cognate gene. To 
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further examine the functional implications of the observed differential methylation, real–time PCR 
expression (RT-PCR) analysis was performed for several of the transcription factors using two B-cell 
lymphoma (Z-138 and SU-DHL) cell lines, one T-cell leukaemia (Jurkat) and one T-cell lymphoma 
(Karpas-299) cell line. For the RT analysis, intron-spanning assays were used with GAPDH mRNA as 
a relative reference for expression normalization. The relative expression was calculated according to 
Muller et al. (134) by averaging normalized expression values of three independent RT measurements. 
All four cell lines were analyzed for DNA methylation in several of the regions described above, some 
of them are shown in Figure 4-14. The averaged methylation level of differentially methylated regions 
was plotted against the normalized expression in Figure 4-15. 
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Figure 4-14 Methylation profiles of selected 5’-UTR regions in B- and T-cell cancer cell 
lines. In total, two B-cell lymphoma cell lines (SUDHL4, Z138), one T-cell leukaemia cell line (Jurkat) and 
one T-cell lymphoma cell line (KARPAS 299) were analyzed. 
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Figure 4-15 Averaged DNA methylation and mRNA expression for selected transcription 
factor genes. Averaged methylation values of amplicons located within the 5’-UTR of each gene and cell 
line are shown (x-axis). Gene expression was measured by real-time PCR and normalized against 
GAPDH (y-axis). The expression values shown are mean values derived from three independent 
experiments; the error bars indicate the standard deviation (SD). 
 
The strictest correlation between methylation pattern and expression was found for the SPI1 gene. 
Here, the hypermethylated CpGs of the T-cell cell lines (Jurkat and Karpas299) correlates with no 
expression, while hypomethylation in the B-cell lines correlates with an elevated level of SPI1 mRNA 
(Figure 4-15). A cell-type independent pattern was observed for the TCF7 gene: relevant expression 
was measured only in the T-cell Jurkat clone, where the average methylation level of TCF7:4 was 
measured with 0%, while the T-cell Karpas line (90% methylation) shows more than ten times lower 
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relative expression. Expression of TCF7 in the B-cell lines is very low, regardless of the methylation 
pattern (Figure 4-15). 
Etv5 was differentially methylated between B-cell lines and T-cell lines in both analyzed regions. The 
upstream region Etv5:1 is hypermethylated in the B-cell lines (100% in Z-138 and 60% in SU-DHL) and 
hypomethylated in the T-cells (0% in both) (Figure 4-14), a pattern which is inversed in the intragenic 
Etv5:2 (data not shown). The highest expression of Etv5 was found in both T-cell lines suggesting 
Etv5:1 as more likely to harbor a regulatory region (Figure 4-15). Etv5:1, in contrast to Etv5:2, also 
shows differential methylation in the hematopoietic cascade data, underlining the above assumption. 
Relatively high levels of Eomes mRNA were measured in both T-cell lines, while the expression 
dropped in the B-cell lines. Differential methylation between T-cells and B-cells was measured only 
within Eomes:3, where the T-cell lines were found to be hypomethylated, while the B-cell lines showed 
an increased level of average methylation (100% in Z-138 and 40% in SU-DHL4). 
GATA3 mRNA was detected only in the Jurkat T-cell line (25% average methylation for GATA3:2) but 
not in the two B-cell lines and in Karpas-299 (>50% average methylation) suggesting here, too, a 
correlation between hypomethylation and expression. 
Similarly, Hlx mRNA level is highest in the Karpas T-cell line (0% average methylation). An increased 
level of methylation as measured in the other cell lines correlates with a drastic decrease of the mRNA 
level (Figure 4-15). FOG1 expression is also highest in the hypomethylated cell lines (Jurkat, SU-DHL 
and Z-138) regardless of the cell type, while it quickly drops for the case of Karpas-299 where the 
average level exceeds 20% methylation (Figure 4-15). 
No significant correlation between differentially methylated regions and measured expression could be 
determined for Th-POK, NOTCH1, c-MAF and TBX21 (Figure 4-15 and data not shown).  
Overall, these results suggest that specific CpGs within the analyzed regions might be responsible for 
the drastic pattern of expression changes between the individual samples. The approach of averaging 
the methylation levels over larger stretches of DNA is a rather rough quantification of the real 
methylation events occurring in the cell at a certain locus and possibly having an influence on the 
expression phenotype. The impact of methylation on the expression can be limited to as few as 1 CpG 
as shown recently for the IL2 gene (57), which may explain in part some of the weak correlations 
detected here. 
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4.3. Targeted approach to biomarker identification by 
means of differentially methylated regions 
4.3.1. T-helper cell imbalances in the peripheral blood of patients 
with rheumatoid arthritis detectable by DNA methylation 
In order to determine a potential diagnostic application for a strongly differentially methylated marker as 
represented by the IFN-γ locus, a quantitative measurement of methylation was performed on memory 
and naive CD4+ cell compartments obtained from six healthy volunteers and nine patients with 
rheumatoid arthritis (RA). CD4+CD45RA+ (naive) and CD4+CD45RO+ (memory) cells were isolated 
as described in chapter 3.1.4. Equal cell numbers from each sample type were used for DNA 
extraction. All nine RA patients were within an acute phase of disease during sample extraction and 
had not yet undergone any immunosuppressive treatment. 
The methylation pattern of all samples was determined within the IFNγ regions 1, 2, and 3, and the 
individual methylation levels obtained for each CpG were averaged per patient / donor within each 
region, assuming an equal level of methylation for adjacent CpGs. The results are displayed as box 
plots in Figure 4-16. 
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Figure 4-16 Box plots of averaged methylation levels for rheumatoid arthritis patients 
(RA) and healthy volunteers. Genomic regions 1, 2, and 3 of the IFNγ  were analyzed within naive and 
memory CD4+ T-cell subsets and compared between patients and healthy donors. Two-sided t-test p-
values were calculated to quantify the significance of the differentially methylated region within the 
memory cell compartments of healthy donors and RA patients. 
 
The averaged methylation levels of the naive cell compartment are for both, RA patients and healthy 
donors and within every investigated region higher than 95% (Figure 4-16). This finding is in agreement 
with the high methylation levels observed in IFN-γ- cells (Figure 4-9). The averaged methylation levels 
for the more differentiated memory cells, however, differ significantly between RA patients and healthy 
donors for the IFNγ regions 1 and 3, respectively (Figure 4-16). No significant difference was seen 
within region 2. IFNγ region 1 is an enhancer element approx. 4.0 kb upstream of the TSS while region 
3 is part of the proximal promoter covering the TSS and exon1. Within region 1, the mean average 
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methylation value in CD4+ memory cells of healthy individuals is approx. 60% while that of RA patient 
reaches approx. 85%. Similarly, within region 3 the mean average methylation value of healthy 
individuals is of approx. 45% and that of RA patients of 60%. Thus, both regions show slightly elevated 
levels of methylation within the RA patient group. 
Statistical significance of the data was confirmed by a t-test: highly significant shift towards a more 
methylated status of these regions exists within RA patients (p < 0.009 for region 1 and of p < 0.007 for 
region 2). The question imposed by this data is: (1) do memory Th1 cells of RA patients have in 
general higher methylation levels than those of healthy individuals or (2) is the Th1/Th2 peripheral 
blood balance within RA patients shifted towards an increased number of Th2 cells? To address this 
question, IFN-γ+ were separated from IFN-γ- CD45RO+ memory cells from a subset of patients and 
from two healthy individuals for control purposes. The determined methylation levels are displayed 
qualitatively as heat charts in Figure 4-17. 
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Figure 4-17 DNA methylation levels in IFN-γ- and IFN-γ+ memory cells of patient with RA 
and healthy individuals 
 
As previously shown for the IFNγ gene locus (Figure 4-9), IFN-γ+ and IFN-γ- cells show here too 
significant differential methylation for several CpGs in the analyzed regions 1, 2, and 3 regardless of 
the health status (p < 0.003 for healthy and p < 0.0005 for RA patients respectively). However, no 
significant difference in methylation could be determined between the IFN-γ+ cells of patients with RA 
and healthy individuals (p < 0.89). Apart from slightly elevated methylation levels measured in 
individual samples (e.g. sample 04 in the RA IFN-γ+ group), the general methylation of both IFN-γ+ and 
IFN-γ- cells does not differ in RA patients and healthy individuals at the IFNγ gene locus.  
Taken together, these results indicate that peripheral blood of patients with RA harbors an increased 
number of Th2 cells and thus sustains previously published findings by (122) and (123). Moreover, a 
DNA methylation marker was for the first time successfully applied to quantify cell balances within a 
mixed cell population. 
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4.3.2. Methylation profiles of the IFNγ and IL10 gene in 
endometriosis 
For many years, the immune system was considered to be involved in the development of 
endometriosis. Many women with endometriosis display certain immunologic defects or dysfunctions. 
Whether this is a cause or effect of the disease remains unknown. Endometriosis is associated with 
changes in both cell-mediated and humoral immunity. As an example, macrophages, which would be 
expected to clear endometrial cells from the peritoneal cavity seem to enhance their proliferation by 
secreting growth factors and cytokines (154). 
It has also been shown that reactive T- and NK-cells are frequently found in the endometrium of 
women with endometriosis as compared to their healthy counterparts and that the eutopic 
endometrium in women with endometriosis tends to express a large variety of cytokine genes (155). 
The data presented here is part of a large candidate gene project aimed at identification of defects in 
DNA methylation detectable in the endometrial tissue of affected women. However, due to current 
efforts to ensure the intellectual property, not all data can be shown here. 
Since inflammatory parameters (cytokines, chemokines, etc.) were reported to be present in the 
peritoneum of woman with endometriosis and in the endometrium (156), DNA methylation for these 
factors was profiled in the endometrial cells of ten non- endometriosis women and ten endometriosis 
patients. The results are displayed as methylation heat charts in Figure 4-18. 
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Figure 4-18 DNA methylation profiles in endometrial biopsies of patients with 
endometriosis (right column) versus non – endometriosis controls (left column). Selected regions within 
the IL10 and IFNγ gene were profiled. Region numbering and genomic position is according to Figure 4-4 
B and 4-9 respectively. 
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As for the two cytokines of relevance in this work, IFN-γ and IL-10, no significant differential 
methylation pattern could be detected within the two groups for none of the two genes. 
Although there is considerable inter – individual variance within the groups, as seen for example in 
region 6 of the IL10 gene, the pattern did not show the desired discrimination between healthy and 
disease. The IFNγ locus is strongly upmethylated for all three investigated regions suggesting a tissue 
specific silencing of this gene in the analyzed endometrial stromal cell. Eventual IFN-γ secreting 
residual T-lymphocytes in the endometrium could not be quantitatively detected by the used 
sequencing technique. Interestingly, the most 5’ CpG of the IL-10 region 5 located at position -86, 
which has been intensively discussed in chapter 4.1.3.2 is methylated at about 50% in most 
endometrial samples as seen in the IL-10- lymphocytes (Figure 4-4 B). 
Since endometrial stromal cells do not express IL-10, a monoallelic expression mechanism could be 
proposed regarding the importance of the methylation information carried by this specific CpG. 
4.3.3. Testing selective methylation marker in tissue biopsies of T- 
and B-cell lymphomas 
As aberrant methylation is a frequent phenomenon in cancer development and progression, the 
methylation profiles of the described transcription factors in T- and B-cell lymphomas were analyzed. 
For this analysis, samples from patients diagnosed with either diffuse large B-cell lymphoma (DLBCL, 
n=20) or T-cell non-Hodgkin lymphoma (n=14) were included and normal lymph nodes (n=18) were 
used as controls. For each tissue sample, histological examination was performed and only those 
samples with a confirmed tumor content of greater than 85% were included in the study, thus ensuring 
a relatively homogenous tumor composition. 
Significant methylation differences at several genomic loci in DLBCL samples as compared to either 
normal lymph nodes or T-cell NHL samples were measured. Figure 4-19 shows the measured 
methylation levels for each CpG in selected genes and regions. A broader overview of DNA 
methylation in the tumor samples versus controls is given by Figure 4-20 where averaged methylation 
of co-methylated CpGs per sample is shown in box plots with each box plot summarizing one disease 
entity. Statistical significance for the measured methylation difference was determined by assessing 
the difference in the means and the variance for each displayed disease entity (Wilcoxon test).  
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Figure 4-19 Methylation profiles of selected TF regions in diffuse large B-cell lymphoma 
(DLBCL), T-cell non-Hodgkin lymphomas (NHL) and control (healthy) lymph node samples. Rows show 
the methylation levels of individual CpGs. Samples and disease states are represented in columns. 
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Figure 4-20 Box plots displaying averaged methylation levels for several analyzed genes 
and regions. Each box plot contains data from several samples analyzed within the respective disease 
entity. The median is shown as black bar. 
 
The genes showing the most prominent differences in DLBCL samples were c-MAF, TCF7, Eomes and 
SPI1 (Figure 4-19 and Figure 4-20. Hypermethylation of two CGIs associated with c-MAF (c-MAF:5, 
Figure 4-19) and TCF7 (TCF7:3, Figure 4-19) was observed. The c-MAF associated CGI was 
hypermethylated (>90% methylation) compared to the methylation of normal lymph nodes (0%) in more 
than 50% (11 out of 20) of the DLBCL patient samples. Similarly, the TCF7 associated CGI (TCF7:3, 
Figure 4-19) showed increased methylation (>60%) in 50% of the analyzed DLBCL samples (10 out of 
20). Most of the DLBCL samples with a hypermethylated TCF7 CGI were hypermethylated within the c-
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MAF CGI as well. Interestingly, the CGIs of both genes were hypomethylated in normal B-cells (Figure 
4-13) indicating that hypermethylation of these two CGIs is a specific event in DLBCL. 
Eomes region 2, located approximately 1.0 kb upstream of the TSS (Figure 4-12), was specifically 
hypermethylated (>60%, p   0,001) in 90% of the DLBCL samples compared to normal lymph nodes 
(Figure 4-19). Although the Eomes TSS is located within a CGI, this CGI remained unmethylated in 
most cases (region 3) but the adjacent region 2 (Figure 4-19) was consistently hypermethylated in 
DLBCL samples. In contrast to the Eomes methylation in DLBCL, normal naive and memory B-cells 
displayed an average methylation (below 30%) in this region. Hypermethylation was often detected in 
the same samples at several gene loci, e.g. DLBCL samples # 3, 4, 5, 6, 8, 11, 12 and 20 were 
consistently hypermethylated within c-MAF, TCF7, Eomes and FOG1. 
The 5’-UTR of SPI1 was unmethylated in almost 80% of the DLBCL samples (Figure 4-19). This 
methylation status corresponds well with the profile observed for healthy B-cells and the two cancer B-
cell lines analyzed (Figure 4-13 and Figure 4-14). In contrast, normal lymph nodes and the T-cell NHL 
samples showed hypermethylation (>50%) in this region. This methylation difference might reflect the 
differing cell type compositions present in healthy peripheral lymph nodes as compared to lymph nodes 
from DLBCL patients. The CGI of FOG1 (region 2, Figure 4-19) showed increased methylation levels 
(>50%) in some DLBCL samples (6 out of 20) as compared to those measured in normal lymph nodes 
and the T-cell NHL group (<10%). Other analyzed genes, such as TBX21 (Figure 4-19), Hlx and 
GATA3 (Figure 4-19) showed no statistically significant methylation differences between the analyzed 
groups, although methylation heterogeneity was measured in some DLBCL cancer samples and not in 
normal lymph nodes. Similar to the methylation profiles derived from healthy cells of the hematopoietic 
cascade samples, no methylation alterations for Th-POK, NOTCH1, STAT1 and STAT6 could be 
identified in any of the lymphoma samples analyzed (Figure 4-19). 
In contrast to the aberrant methylation observed in the DLBCL group, no recurring methylation 
differences between T-cell NHL samples and normal lymph nodes could be measured for the genes 
analyzed in the study. In the T-cell NHL group, only one sample (# 10, Figure 4-19) showed 
hypermethylation in some regions, however this observation did not reach statistical significance. In 
other analyzed samples and loci, T-cell NHL and normal lymphatic tissue showed indistinguishable 
methylation profiles (Figure 4-19 and Figure 4-20). 
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5. Discussion 
In the current study, the DNA methylation profiles of major cytokine genes and transcription factors 
relevant during lymphopoiesis were determined at several CpGs spanning the respective gene loci.  
The predominant method used to quantify methylation was the direct bisulfite sequencing. 
For the IL10 gene, epigenetic features beyond DNA methylation, specifically histone modifications 
were assessed, thus allowing a deeper insight of the chromatin status at this gene locus.  
The aims of this profiling were twofold: (1) to gain insights into the epigenetic effects participating in the 
cell-specific regulation of these genes and (2) to identify differentially methylated regions that may 
allow the use of these markers directly or indirectly as surrogate markers in clinical diagnostic. To 
obtain accurate and robust methylation data from each of the analyzed cell types and for each 
investigated region, a direct PCR bisulfite sequencing technique with subsequent methylation – specific 
software analysis was applied. 
As DNA methylation is a tissue specific feature in metazoan, different cell types of the human immune 
system were analyzed and the methylation levels were compared between cell types according to the 
defined biological question. A major cell type in which DNA methylation of cytokine genes was 
interrogated are CD4+ T-lymphocytes and their naive and memory subsets. Differentially methylated 
regions discovered in the IFNγ and IL10 gene were used to interrogate their methylation status in 
indications like rheumatoid arthritis and endometriosis and to evaluate their potential as diagnostic 
biomarkers in these diseases. 
Transcription factor gene methylation was analyzed in hematopoietic progenitor cells, in naive and 
mature B-cells as well as CD8+ cells, and in the T-helper cell subpopulation of CD4+ lymphocytes. 
Further, differentially methylated markers obtained for the transcription factor comparisons within 
hematopoietic cellular differentiation were investigated in two human hematopoietic neoplasias, T-cell 
and B-cell non Hodgkin lymphoma, and compared to non – affected, “normal” lymph node methylation.  
During cell differentiation processes, several epigenetic modifications at the loci of effector cytokine 
genes such as IFNγ, IL4 / IL13, and IL2 were demonstrated in Th-cells. These included effects like 
DNA demethylation, histone hyperacetylation, development of characteristic DNAseI hypersensitivity 
patterns, increased restriction enzymes accessibility, and rearrangement of the chromatin within the 
nucleus (157), (158), (159), (160). An emerging view is that helper T cells use the above mentioned 
epigenetic mechanisms to allow dividing cells to memorize, signalling events that occurred earlier in 
their development (35, 161). As the only epigenetic modification for which an inheritance mechanism is 
known (maintenance methylation), DNA methylation is likely to mediate the restoration of DNAseI 
hypersensitivity sites following replication (162). 
Differentiation of precursor naive T cells into mature cytokine producing cells is initiated by stimulation 
of naive T cells through the T cell antigen receptor (TCR) and influenced by a large number of genetic 
and environmental variables including the cytokine milieu (163), (164). Mature Th1 and Th2 cells are 
characterized by their specific, non-overlapping pattern of cytokine expression. The “poised” chromatin 
Discussion  Page 73 
state apparent in effector/memory Th-cells is thought to allow rapid secretion of effector cytokines 
when re-challenged by invading pathogens. 
It has been shown for IL-4 and IFN-γ that DNA demethylation is not required for the transcription per se 
but that demethylation at the specific loci promotes high levels of cytokine production in fully 
differentiated, mature T-helper lymphocytes (146), (56).  
The demethylation events in cytokine competent cells occurs in the proximal 5’ promoter region, further 
upstream at specific locus control regions (LCRs) and within the gene body (140), (102), (103). In the 
case of IL-2, as few as one single CpG was shown to confer competency for efficient IL-2 production 
(57). 
5.1. Quantitative direct bisulfite sequencing: advantages 
and shortcomings 
The major method used to characterize DNA methylation in the in the present study was the 
quantitative sequencing of PCR products obtained after amplification of bisulfite converted DNA (84). It 
is based on the calculation of methylation signals by quantifying the cytosine/thymine proportions at 
CpG dinucleotides in the pre-processed sequence traces. 
The method was developed at the Epigenomics AG to meet the requirements of the Human 
Epigenome Project (HEP). There, it has been successfully applied to generate high resolution 
methylation profiles of the human chromosomes 6, 20, and 22, where approximately 1.9 million 
individual CpG methylation values were measured in a total of 12 different human tissues (33). 
The direct bisulfite sequencing is especially useful in generating high resolution profiles of methylation 
levels at individual CpGs located in cis on stretches no longer than 500 bp on the DNA sequence. 
It is a high throughput method, which bypasses laborious cloning and sequencing of PCR products. 
There is no restriction regarding the sample DNA origin, which can be analyzed by this method, and 
the analysis can be performed on as little as 100 ng initial DNA due to the amplification step 
immediately following bisulfitation. 
Thus, the method allows parallel screening of large numbers of CpGs in several different tissues at the 
same time. Subsequent computed data analysis helps to generate comparisons between individual 
genomic regions and between DNA originating from different tissue types. 
The results of the sequencing are usually displayed in this work as methylation levels of individual 
CpGs in the heat charts. In some cases, when adjacent CpGs have similar methylation levels, the 
individual levels were averaged to obtain the methylation pattern of an entire region (Figure 4-11, 
Figure 4-13 B, Figure 4-15, Figure 4-16 and Figure 4-20). This averaged quantification makes the data 
more robust to small variations between individual CpG levels resulting from incorrect level 
quantification. 
Like every other laboratory method, the direct bisulfite sequencing also has its limitations, especially 
when it comes to accurate quantification of methylation levels with error rates lower than 15%-20%. 
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First, the efficiency of the bisulfite reaction is of crucial importance for the successful approximation of 
the methylation level at any given CpG. The efficient bisulfite conversion of genomic DNA is not only 
dependent on adequate reaction conditions. Factors like the chromatin status at a certain region affect 
the conversion rate substantially. It has been observed that methylation levels of CpGs located in 
heterochromatin are more difficult to quantify than CpGs located in active chromatin. Incomplete 
conversion of DNA results in incorrect normalisation and finally leads to inaccurate quantification of the 
methylation signal. 
The normalisation information is derived from the conversion rates of cytosines outside of CpG 
dinucleotides, calculated from the area under the sequence trace curve. This rate is usually calculated 
by two different methods and overall conversion rates below 85% led to the exclusion of the respective 
sequence trace from the analysis. 
The primers used to amplify the bisulfited DNA are positioned on regions depleted of CpGs in order to 
avoid inefficient amplification due to the C/T polymorphism generated after bisulfite conversion at 
unmethylated CpGs. However, for not yet entirely clear reasons, some primer assays tend to amplify 
specific methylation conformations out of the heterogeneously methylated DNA stretch. This 
phenomenon, known as “PCR bias”, leads to wrong assignment of the methylation composition of a 
given sample (165). In order to determine the bias introduced by any of the primer assays used in this 
study, every assay was used to sequence artificially generated up- and downmethylated DNA as well 
as 50% mixtures of the upper two DNA types. Assays, failing to calculate the expected levels, 
especially in the mixed DNA sample, were discarded from the study. Nevertheless, at some CpGs 
located at the periphery of the analyzed regions, the methylation signal is difficult to quantify mainly 
due to the high proportion of mixed signals. This resulted too in inaccurate quantification of these loci. 
The average level of discrimination for all employed assays was 30% methylation differences between 
individual samples. 
In order to account for much of the noise derived from the described method inaccuracy, replica 
biologic samples were employed and repeated PCR amplification and sequencing reactions were 
performed.  
Altogether, the method helped to characterize consistent methylation differences between sets of 
samples and to discover previously uncharacterized DNA methylation markers. 
5.2. Methylation profiling at the IL4, IL13, GATA3 and 
TBX21 loci in CD4+ subsets  
The genes encoding the cytokines IL-4 and IL-13 as well as the transcription factor GATA-3 are 
predominantly expressed in Th2 cellular subsets of the CD4+ cells (140). IL4 and IL13 are part of a 
locus of co-regulated cytokines which also contains the IL5 and RAD50 genes (Figure 4-3 A). In this 
work, the methylation profiling of a large number of CpGs located near and within these gene loci were 
analyzed in T-cells that do not express IL-4 and IL-13. 
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Differentially methylated regions were observed in the previously described locus control region (LCR) 
between the IL4 and IL13 gene (Figure 4-3 A, region 3) as well as within the exon 1 and exon 2 of the 
IL4 gene (Figure 4-3 A, region 5 - 9). In contrast to the naive precursor cells, depicted as IL-10-/IFN-γ-, 
where the methylation levels of nearly every measured CpG exceeded 90%, methylation of the 
memory cell subsets IL-10+ / IFN-γ+ and IFN-γ+ drops to levels of about 50% - 60%. IL-10+ memory 
subsets show intermediate levels, usually higher than 60%. It is known, that low-level non selective 
transcription of the IFNγ, IL4 and IL13 genes occurs in naive T-cells following stimulation with antigen, 
indicating that these genes are poised to respond to the signals that induce differentiation (166). Thus, 
DNA methylation information can be overridden to induce transcription and is later used as a “lock in”-
mechanism to maintain stable transcription in fully differentiated cells. Although the current analysis 
was not performed in Th2 cells, where complete demethylation is known to occur following stable 
transcription establishment, the reduced methylation levels in the memory cell subsets are remarkable. 
They suggest that epigenetic modifications of the loci towards complete demethylation occurs gradually 
and sporadic rather than from one cell division to the other or directly by a targeted DNA demethylation 
event. The hypothesis could be set up, that upmethylated, antigen-inexperienced naive cells become 
gradually demethylated at the cytokine gene loci, ultimately leading to very low methylation levels for 
the expressed cytokines. The loci of the other cytokines remain at an intermediate level of methylation 
allowing a “mixed lineage” status. Definitive cell fate determination towards Th1 or Th2 lineage occurs 
therefore later during differentiation and not after first antigen contact of the naive T-cell. 
The cell populations used for methylation analysis within this study have been sorted to a purity of 
greater that 90% and the analysis of methylation by bisulfite sequencing has a resolution capacity of 
20% methylation differences (data not shown). It cannot be excluded that phenotypically identical cells 
obtained by a defined purification method have different methylation patterns and constitute a mixed 
cell population. However, the methylation pattern at a specific genomic locus of a cell population that 
has been purified according to expression of the respective region is expected to be the same in the 
targeted cells. 
Interestingly, the intermediate methylation state does not allow the cell to return to transcription at the 
respective loci since studies are available where it was shown that once committed memory cells are 
not able to return to the point before definitive commitment. 
However, more profound studies of the methylation dynamics are required to fully demonstrate the 
upper statements. 
The methylation of the GATA3 gene showed the same pattern in all of the analyzed cell types. At this 
point of differentiation, DNA methylation is not correlated to the gene transcription as its expression 
was significantly up-regulated in IL-10+IFN-γ- versus IL-10+IFN-γ+ Th-cells. The zinc finger transcription 
factor GATA-3, apart from its key role as Th 2 cytokine regulator, is known to be expressed already in 
hematopoietic progenitor cells (36). As frequently described for CpG islands, the island associated to 
the GATA-3 gene is demethylated at several analyzed CpGs and within the conserved regions located 
within and outside the island (Figure 4-3 B). The low degree of methylation is correlated to the high 
degree of sequence conservation found in the CpG island (Figure 4-3 B, CNS row). 
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A clearer differentially methylated pattern is displayed by the TBX21 locus. As the transcriptional 
regulator TBX21 is essential for transcription of the IFN-γ  gene in Th1 cells (137), its methylation 
pattern correlates with the TBX21 expression in IFN-γ+ cells. Interestingly, the regions of low 
methylation in TBX21 expressing cells are both located within the first intron, suggesting an as yet 
unknown regulatory role within the conserved elements they are covering (Figure 4-3 C, region 2 and 
3). 
Again, the CpG island located at the 5’ end of the TBX21 gene and harboring a large conserved DNA 
region is demethylated in all analyzed samples underlining the role of demethylation for the 
evolutionary conservation of DNA sequences. 
5.3. Absence of differential methylation at the IL10 gene 
locus: consequences for the functional memory 
Although the immunoregulatory role of IL-10 has been extensively studied for decades, little 
information is available on the molecular mechanism of its transcriptional regulation in humans. 
Aspects of epigenetically related expression memory, conferring rapid reactivation of the IL10 gene in 
committed Th1 and Th2 cells have not yet been addressed. 
As an approach to this question, the methylation of 48 CpGs encompassing the IL10 locus was 
measured in IL-10+ and IL-10- CD4+ memory cells obtained directly from the peripheral blood of 
healthy donors. Simultaneously, Th1 and Th2 cell lines with IL-10 expressing and non-expressing 
properties were analyzed for methylation. The methylation results from both ex vivo cells and cell lines 
showed similar methylation patterns. In contrast to the findings of extensive locus demethylation for 
e.g. the IFN-γ gene in IFN-γ+ cells, no such clear pattern emerged for the IL10 gene. The IL10 locus is 
rather CpG poor and most of the CpGs located upstream of the annotated transcription start site were 
upmethylated regardless of IL-10 transcription (Figure 4-4 A, B) suggesting no regulative role for DNA 
methylation in the analyzed T-cell subtypes. A more interesting region with respect to differential 
methylation between the cell types is region 5, located in close vicinity to the TSS and within a highly 
conserved DNA sequence. The two most 3’ analyzed CpGs within these region, located at positions -
161 and -86 display slight methylation differences between the IL-10+ and IL-10- cells in both analyzed 
systems, the ex vivo cells and the Th cell lines. IL-10 expressing cells tend to be demethylated at these 
two CpG positions, a finding that could be strengthened by the sequencing of cloned PCR products 
obtained from region-specific amplification of the bisulfited DNA (Figure 4-5). The histone modification 
data obtained for region 5 sustains the notion of an open chromatin state in the region (Figure 4-6). 
Previous studies investigating DNAseI hypersensitivity sites (HS) in naive and differentiating murine T-
cells identified this conserved region as a Th2 specific, constitutive HS and also found the 
corresponding murine CpG at position -86 to be demethylated in IL-10 expressing cells (99). Taken 
together, these data suggest a regulative role of this proximal promoter region in T-cells expressing IL-
10 in the human immune system. 
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Next, we addressed the relevance of methylation level of the two conspicuous CpGs in memorizing the 
ability of IL-10 expression. Answering this question becomes easier when comparing expression in 
view of the methylation pattern for the two cytokines IL-10 and IFN-γ. Clonal in vitro expansion for two 
weeks of CD4+ T-cells expressing IL-10, IFN-γ or both cytokines revealed a strong tendency of IL-10 
expression loss upon restimulation (Figure 4-7). Simultaneously, the two promoter CpGs maintain the 
lower methylation status observed previously (Figure 4-8). At the same time, IFN-γ expressing cells 
being extensively demethylated at the entire gene locus maintain the expression of this cytokine 
throughout the incubation time. Thus, the promoter DNA methylation of the IL10 gene might not harbor 
the “locked in” expression memory for this cytokine as it does in the case of IFN-γ. 
The unique role of IL-10 with its broad immunoregulatory functions might be a major reason for these 
differences in expression and regulation. Recent studies have demonstrated that IL-10 produced by the 
human Th1 cells has a regulative effect of limiting exaggerated inflammation in animals infected with 
Toxoplasma gondii (167), (168). It has been suggested that the IL10 locus might be in a reversible 
histone deacetlyase – responsive state in Th1 cells that allows its reactivation upon continuous 
stimulation by chronic infection. A constitutive expression, conferred by an epigenetic memory 
mechanism, would prevent the appropriate inflammatory response and hence reduce immune system 
efficacy. 
In conclusion, IL-10 is excluded from the functional cytokine memory in human Th-cells, preventing the 
generation of memory Th-cells with an inherited program to secrete IL-10.  
5.4. Differential DNA methylation at the IFNγ locus and its 
role as epigenetic memory 
In the current study, the CpG methylation of 28 CpGs located within the IFNγ gene body, the proximal 
promoter and up to 4.0kb upstream of the TSS were profiled in IFN-γ expressing and non expressing 
CD4+ lymphocyte subsets. The analyzed regions are highly conserved between man and mouse as 
revealed by interspecies sequence comparisons. In agreement with previously reported data, strong 
demethylation was found at the 4.0 kb upstream enhancer element and at the CpG located -53 bp 
upstream the TSS in IFN-γ competent cells (169). Upmethylation of the latter CpG was shown to be 
sufficient for transcriptional silencing of the IFN-γ gene in Th2 cells (55).  
The results in the current study reveal an extensive demethylation of several CpGs across the IFNγ 
locus including a number of CpGs within the gene body up to exon 3. As the methylation levels of IFN-γ 
expressing cells were determined at about 0 %-10% methylation and of IFN-γ non expressing cells at 
80 – 100% methylation (Figure 4-9), demethylation of both alleles seems to be required for stable 
expression competence. The DNA demethylation at the IFN-γ locus confers the cell the stable property 
to rapidly express IFN-γ upon restimulation as seen in the in vitro cultivation and restimulation 
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experiment (Figure 4-7). Over 95% of the cells were still able to express IFN-γ after one week of 
cultivation. 
The in vitro experiments performed to induce differentiation of naive cells towards the Th1 IFN-γ 
expressing phenotype (chapter 4.1.4.2) revealed a strong dependency of the demethylation on the 
externally applied stimulus and a region specific dynamic of this process (Figure 4-10). Cells co-
cultured with allogeneic dendritic cells (stimulus III), secrete themselves several cytokines and growth 
stimulating factors and thus induce the lowest degree in methylation within both, IFN-γ producing and 
non-producing cells. Regions to be first and most prominently demethylated are obviously those 
located in the proximal promoter (region 2 and region 3) and in the enhancer element (region1). 
The stimuli I and II consisting mainly of T-cell stimulatory molecules and one respectively two Th1 
polarisation priming conditions (anti IL-4 and anti IL-4 / IFN-γ for stimulus I and II respectively), only 
induce slight demethylation at the genomic regions 2 and 3 (both located in the proximal promoter) 
suggesting a relative importance of these regions regarding chromatin accessibility. IFN-γ expression 
despite a hypermethylated locus (as seen in region 1 of IFN-γ + cells stimulated with the stimuli I and II) 
was demonstrated to occur through transactivation mediated by the Th1 key transcriptional regulator 
TBX21 (146). However, during the cultivation period of six days none of the stimuli induced total 
demethylation at both alleles within the investigated cells. 
The strong effect in inducing DNA methylation-mediated accessibility at the IFNγ locus conferred by the 
allogeneic dendritic cells in contrast to the cytokine cocktails stimulation may be explained by a 
probabilistic view of cellular polarisation and gene expression. Following this concept, a complex 
promoter as that of IFNγ, requiring several transcriptional initiation molecules, is most likely to be 
activated and made accessible for transcriptional complexes, the higher the number of external stimuli 
that influence the cell to differentiate or to produce the respective cytokine. The probability of 
expression is thus multiplicatively enhanced by each individual stimulus (170). A typical dendritic cell 
presents several antigens on its MHC complexes and releases several stimulatory molecules into its 
cellular surrounding. This increases the probability of the presence of all required factors for inducing a 
stable, accessible configuration at the targeted gene locus. 
To fully elucidate the role of the external stimulus on the cytokine locus accessibility and associated 
expression, a quantification of the produced IFN-γ in the IFN-γ+ cells and individual cell numbers 
obtained in the individual stimulation experiment is necessary. 
5.5. DNA methylation of transcription factor genes 
changes during differentiation  
The results presented in chapter 4.2 reflect the DNA methylation profiles of a number of candidate 
transcription factor (TF) genes that are key for the development of specific cell lineages in the 
lymphopoietic system. It could be shown that differential DNA methylation of several TF genes such as 
SPI1, TCF7, c-maf, Etv5, TBX21 and GATA3 is an accompanying feature during development and 
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lineage commitment. For SPI1, Eomes and Etv5, an inverse correlation between 5’-UTR methylation 
and the respective gene expression was demonstrated, suggesting that these genes are regulated in 
part by DNA methylation. A specific role of the differentially methylated regions in transcription initiation 
has yet to be elucidated. 
The lack of an inverse correlation between 5’-UTR methylation and the respective gene expression that 
has been observed for the other genes is consistent with previous reports (38), (33). These groups 
found an inverse correlation with the transcription of the cognate gene for only about 1/3 of all 
differentially methylated 5’-UTRs.  
Since the current study does not claim a comprehensive screen of all putative regulatory sequences of 
the genes, it cannot be excluded that the methylation of other, adjacent CpGs might also affect gene 
transcription. Methylation of a single CpG as opposed to an entire region might be sufficient to silence 
expression of these TF genes. Indeed, Murayama et al. showed recently for the IL2 gene that 
methylation at a single CpG within the IL2 promoter is sufficient to regulate IL-2 expression (57). 
Alternatively, the differential methylation observed might not directly regulate transcription, but might 
rather reflect a different accessibility of the chromatin (171). 
The 5’-UTR of SPI1 was unmethylated in undifferentiated progenitor cells and naive and memory B-
cells while being hypermethylated in CD4+ and CD8+ lymphocytes. This methylation profile, combined 
with the presented evidence that SPI1 is regulated in part via 5’-UTR methylation, is consistent with the 
reported expression of this TF. SPI1 is highly expressed in early hematopoietic development and 
expression persists in differentiated B-cells but not in T-cells (172), (173). Furthermore, the vast 
methylation profiling data presented here complements the data from Amaravadi and Klemsz, who 
described the tissue specific methylation in B-, T- and macrophage cell lines of three CpGs flanking 
exon 1 of SPI1 (174). In summary, the presented results point to an epigenetic regulation of SPI1 
during hematopoiesis. 
The observed differential methylation profiles of TCF7, c-maf, TBX21, Etv5 and GATA3 indicate that 
there are lineage and differentiation-specific methylation profiles that in turn might help to “lock” and 
memorize a specific state. Furthermore, the observed methylation profiles correlate well with reported 
expression patterns of these genes. Although TCF7 expression did not correlate with its methylation 
status in the cell lines used, the observed low methylation in the primary cells (CD34+ progenitor cells, 
naive CD4+ and CD8+ lymphocytes) correlates with the reported expression of TCF7 in hematopoietic 
progenitor cells (175) and during T cell development (176). 
For c-maf and TBX21, regions located within their 5’-UTR were specifically unmethylated in memory 
Th1 CD4+ lymphocytes and CD8+ lymphocytes. In turn, c-maf is expressed in Th2 CD4+ lymphocytes 
(177) and in CD8+ lymphocytes (178) and TBX21 is expressed in Th1 CD4+ lymphocytes (179) and in 
CD8+ lymphocytes (180). In all examined hematopoietic cells, the Etv5 5’-UTR displayed a low 
methylation, with only Th1 CD4+ and CD8+ memory cells being slightly higher methylated. Etv5 is 
expressed at low levels in both naive and memory Th1 CD4+ cells but is highly expressed in activated 
Th1 CD4+ cells (118) suggesting that DNA methylation might only play a permissive regulatory role in 
these cells. GATA-3, which has been implicated in both early T cell development and the transition of a 
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mature Th precursor cell to the Th2 lineage, is expressed at higher levels in CD4+ as compared to 
CD8+ lymphocytes (181). In the samples used within this study, the 5’-UTR of the GATA3 gene 
showed reduced methylation in CD4+ naive and memory cells as compared to B-cell and CD8+ 
lymphocytes. 
In conclusion, the current study provides evidence for DNA methylation changes throughout healthy 
lymphocyte development in transcription factor genes that are restricted in their expression to particular 
lineages. 
5.6. Differentially methylated regions as diagnostic 
biomarkers 
A biomarker is an endogenous molecule or process that is a specific indicator for the presence of a 
given disease condition in the body. It might be either derived from the disease area itself or the 
response of the body to the abnormal state.  
Within the current study, several regions found to be differentially methylated in the analyzed cell types 
have been tested for their discrimination potential between disease and healthy state. 
Three different disease entities were exemplarily analyzed in the fields of autoimmune disease and 
hematologic cancer. Differentially methylated regions within the cytokine gene IFNγ were used to 
quantify differences in the composition of the memory T –cell compartments of patients with 
rheumatoid arthritis (RA) and healthy individuals. In the field of endometriosis, none of the applied 
markers derived from the IFNγ  and IL10 gene was able to detect significant differences between the 
analyzed disease tissue and its healthy counterpart. In contrast, several markers based on the 
transcription factor genes were found to be differentially methylated between healthy lymph node and 
cancerous lymphatic tissue in the analyzed B-cell neoplasm. Concomitantly, none of them was 
aberrantly methylated in the analyzed T-cell neoplasm when compared to the correspondent healthy 
tissue. 
A controversially discussed topic in the etiology of rheumatoid arthritis is that of a disturbed Th1/Th2 
balance in the peripheral blood. The synovial membrane of patients with rheumatoid arthritis is invaded 
by activated Th1 lymphocytes that locally induce a strong inflammatory environment. It has been 
therefore hypothesised, that accumulation of Th1 cells in the joints of patients with RA results in a 
general depletion of these cell subset in the periphery (122). Figure 4-1 shows schematically the 
hypothesized view regarding the composition of the peripheral blood memory Th cell subsets in healthy 
individuals and RA patients. 
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Figure 5-1 Hypothesized composition of the Th - memory cell compartment in healthy 
individuals and Rheumatoid Arthritis patients. The diminished number of IFN-  + Th1 cells in the 
peripheral blood is possibly the consequence of massive Th1 cell migration into the synovial membrane 
of the affected individuals. 
 
However, controversial results led to a critical view of this hypothesis (182), (183). The methylation-
based measurement performed in the current study is strengthening the hypothesis of diminished Th1 
cell numbers in the peripheral blood of individuals carrying the disease.  
Since the methylation in the IFNγ gene promoter region is strogly discriminating between IFN-γ 
producers and non-producers and thus between Th1 and Th2 cells (Figure 4-9, Figure 4-17), this 
marker was chosen to quantify the cell balance in isolated memory Th-cell compartments. The 
resulting methylation value is a mixed signal obtained from the proportion of unmethylated Th1 cells 
and upmethylated Th2 cells. The analysis was focused on the promoter regions 1, 2 and 3 (Figure 4-9). 
After determining the methylation level for each individual CpG in the respective regions, the averaged 
value was determined for each region and patient. The medians of the two groups (healthy and RA 
patients) were compared and statistically significant differences were determined for the regions 1 and 
3, consisting specifically in a higher methylation level in patients with RA. Since FACS separation of the 
twoTh cell types revealed no irregularities in the methylation of IFN-γ producing Th1 cells (Figure 4-17), 
a possible conclusion is that of a cell balance shift towards Th2 cells within the six RA affected 
individuals analysed in this study. 
However, before putting this data into a clinical context two limitations of the study need to be 
considered: first, the small sample numbers especially in the control group and second, the 
measurement method of averaged bisulfite sequencing methylation values. 
The limitations of the measurement method is discussed in detail in chapter 5.1. In order to minimize 
the data background obtained from a single CpG measurement, the methylation values across a DNA 
stretch of the size of e.g. region 1, 2 or 3 were averaged for each sample. The averaged data were 
used for the comparison of the means between the two defined groups. 
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In order to obtain a homogenous group of RA patients, a set of criteria had to be defined, such as 
heterogenous gender distribution, disease stage and most important, the patient therapyat the time of 
blood withdrawal. The nine patient samples included in the study were obtained from individuals 
suffering an acute RA phase and prior to any anti-inflammatory drug treatment. 
The disease phase at the time point of sample withdrawal was determined by physical symptom 
classification rather than by evaluation of clinical parameters such as the C-reactive protein (CRP) 
level. Literature data shows a strong direct correlation between high CRP levels (and thus strong 
disease activity) and the depletion of Th1 cells in the peripheral blood (123). Hence, the information on 
the respective CRP level of each patient would have been a useful parameter in the further 
classification of the nine patient samples. 
Especially the last mentioned condition (no previous medication), is essential since anti-inflammatory 
drugs may have an influence on the cell composition in the peripheral blood. At the same time, this 
prerequisite is rendering sample collection difficult since most patients have a long history of non 
steroidal antiinflammatory drug (NSAID) or corticosteroid drug treatment. Thus, we had to limit our 
study to the available nine patient and six control samples.  
The results obtained with the current patient cohort point to a shifted balance of Th cells in the 
peripheral blood of RA patients towards Th2 cells. 
An incomplete demethylation and thus maturation of Th1 cells at the IFNγ locus is improbable, since 
IFN-γ+ CD4+ cells sorted by FACS from the blood of RA patients showed the usual low methylation 
levels as described in healthy individuals for this cell type. Thus, the observed increase in methylation 
is most likely to be derived from a shift in the Th1/Th2 balance. 
Until now, relatively few studies have been addressing this issue, mainly because clinical diagnosis of 
RA is increasingly performed by the identification of specific antibodies present in patients carrying the 
disease. In addition, shifts in the balance of cellular compartments may be an unspecific event 
accompanying the course of the disease rather than the cause. 
However, the quantification of cell compartments via DNA methylation performed in the current study is 
useful for two reasons: first, it simplifies the general procedure of FACS cell counting, intracellular 
cytokine staining and/or mRNA measurement that are currently used to determine cellular ratios. 
Second, it could be used to monitor the efficacy of a given therapy in restoring the natural cellular 
balance. 
Cell specific methylation patterns could be further used in several applications. For example, Saito at al 
described a significantly higher Th1/Th2 ratio in patients with preeclampsia, a severe pregnancy 
disorder which results in premature birth (184). The development of a methylation based test to 
determine the cell ratios would help to carefully monitor the pregnancy and to evaluate the risk of 
preeclampsia at early stage.  
Although not for the use in peripheral blood, another possible application of T-cell specific methylation 
markers is the assessment of the number of infiltrating lymphocytes in tumors. High levels of specific 
CD4+ lymphocytes (Treg cells) in tumor tissue of ovarian cancer have been reported to be associated 
with a poor disease prognosis (185). Since immune surveillance plays a significant role in cancer 
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development, the presence and the quantification of lymphocytes in the environment of solid tumors 
might be of crucial importance for prognosis and even therapeutic prediction. 
As for the two markers tested in endometriosis (IL10 and IFNγ) no significant methylation differences 
could be detected that enable discrimination between patients and healthy individuals. These 
lymphocyte markers were tested in endometrial tissue with the expectation of detecting infiltrates that 
are indicative of an inflammatory process in the endometrium. For the failure to detect difference two 
possible explanations were considered. First, the methylation detection method of direct bisulfite 
sequencing could be too insensitive to detect small proportions of differentially methylated cells among 
a strong background (see chapter 0 for details). Second, the presence of lymphocyte infiltrates in the 
endometrium was hypothesised upon the finding of severe inflammation in the peritoneum of woman 
with endometriosis. However, the inflammatory reaction at established peritoneal lesions may not be 
present already in the pre-menstrual endometrial tissue thus resulting in the absence of detectable 
numbers of immune cells. 
The third disease class that has been analyzed to detect discriminating methylation markers belongs to 
the field of cancer, where methylation was already abundantly shown to be an important contributor in 
disease establishment (71). DNA methylation biomarkers, which currently possess the most clinical 
relevance, have been developed in the field of tumor classification, disease and therapy prognosis. 
In this study, candidate methylation tags used to assess patterns in the healthy hematopoietic cascade 
were employed to analyse patterns of differential methylation in malignancies of the lymph node. 
Profound changes in the DNA methylation profile of several transcription factor genes (SPI1, TCF7, c-
maf and eomes) were found in diffuse large B-cell lymphoma (DLBCL). 
Compared to normal lymph nodes and T-cell derived lymphomas, SPI1 was unmethylated in most of 
the DLBCL samples. It is possible that this observation reflects the increased number of B-cells in 
lymph nodes derived from DLBCL patients. Alternatively, it is possible that the 5’-UTR of SPI1 is 
specifically unmethylated in DLBCL lymph nodes and contributes to tumorigenesis. Regulation of SPI1 
is crucial for effective cell proliferation control, as Rosenbauer et al. recently reported that mice, 
carrying a deletion of a regulatory element (URE) approximately 14.0 kb upstream of SPI1, developed 
acute myeloid leukemias (106). In conclusion, the presented data suggest a tight epigenetic control of 
SPI1 during hematopoiesis and point to a role of aberrant SPI1 methylation in DLBCL tumorigenesis.  
Although the expression status of these genes was not measured in DLBCL, promiscuous expression 
of TF genes appears to be a common feature of lymphomas. Dorfman et al. found that T-cell 
transcription factors are aberrantly expressed in B-cell lymphoproliferative disorders (186), and 
conversely B-cell transcription factors are aberrantly expressed in T-cell lymphoproliferative disorders 
(187). Additionally, a number of DLBCL patients showed consistent hypermethylation of several genes 
that could point to distinct methylation signatures potentially defining molecular subgroups within these 
patients. Interestingly, a number of genes (e.g. SPI1, TCF7 and c-maf) that were differentially 
methylated in healthy cells were also aberrantly methylated in lymphoma samples, thus potentially 
indicating increased susceptibility of aberrant methylation of these genes during tumorigenesis. 
Currently, the mechanisms that lead to aberrant methylation in tumors are largely unknown, but further 
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genome-wide studies will help determine if tissue-specific methylated genes are more likely to become 
aberrantly methylated in diseased tissues.  
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7. Appendix 
7.1. Materials and Devices 
7.1.1. Buffers 
Buffer Components 
TE 10 mM Tris, 1 mM EDTA 
Sanger buffer 320 mM Tris-HCl (pH 9), 6mM MgCl2 und 10 % [v/v] Sulfolane 
7.1.2. Molecular biology reagents 
Molecular biology reagents Supplier 
Agarose Eurogentec, Cologne, Germany 
Brefeldin A (C16H24O4, MW = 280.36) Sigma-Aldrich, Dorset, UK 
Bovine serum albumin (BSA) Fermentas, St. Leon-Rot, Germany 
DEPC treated water Fluka Chemie, Buchs, Swiss  
Dinucleotidetriphosphates (dNTPs) Fermentas, St. Leon-Rot, Germany 
1,3-Dioxane (C4H8O2, MW = 88.11) Merck KGaA, Darmstadt, Germany 
Dulbecco's Modified Eagle Medium (DMEM) (culture media) PAA Laboratories GmbH, Innsbruck, 
Austria 
Ethidiumbromid (C21H20BrN3, MW = 394.31) Merck KGaA, Darmstadt, Germany 
EDTA ((HO2CCH2)2NCH2CH2N(CH2CO2H)2, 
MW = 292.24) 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Fetal calf serum (FCS) Gibco-BRL, Karlsruhe, Germany 
Formaldehyde (HCHO, MW = 30.03) Merck KGaA, Darmstadt, Germany 
Glycine (NH2CH2COOH, MW = 75.07) Merck KGaA, Darmstadt, Germany 
Granulocye macrophage - colony stimulating factor 
(GM-CSF) 
Roche Diagnostics, Mannheim, 
Germany 
HEPES (C8H18N2O4S, MW = 238,3) Gibco-BRL, Karlsruhe, Germany 
Hi-Di formamide Applied Biosystems, Foster City, USA 
HotStart Taq polymerase Qiagen, Hilden, Germany 
Human Genomic DNA Promega, WI, USA 
Hydrochloric acid (HCl, MW = 36,46) Merck KGaA, Darmstadt, Germany 
Ionomycin (I) (C41H72O9, MW= 709.00) Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
L-glutamine (H2NCOCH2CH2CH(NH2)CO2H, 
MW = 146.14) 
Gibco-BRL, Karlsruhe, Germany 
Lithiumchloride (LiCl, MW = 42.39) Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Natriumdodecylsulphat (SDS) (CH3(CH2)10CH2SO3Na, 
MW = 288.38) 
Fluka GmbH, Buchs, Germany 
Oligonucleotides for PCR amplification and sequencing MWG Biotech AG, Ebersberg, 
Germany 
10xPCR buffer Qiagen, Hilden, Germany 
Phorbol 12 -myristat 13-acetat (PMA), (C36H56O8, 
MW = 616.8) 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Phosphate buffered saline (PBS) Fluka GmbH, Buchs, Germany 
polyT primer MWG Biotech AG, Ebersberg, 
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Germany 
Proteinase K Qiagen, Hilden, Germany 
Random hexamers (oligonucleotides) MWG Biotech AG, Ebersberg, 
Germany 
RNAse A Qiagen, Hilden, Germany 
RNAse Inhibitor Ambion, Foster City, USA 
RPMI 1640 (culture media) PAA Laboratories GmbH, Innsbruck, 
Austria 
S-adenosylmethionine (SAM) New England Biolabs, MA, USA 
Sodium bisulfite (Na2S2O5, MW = 190.11) Merck KGaA, Darmstadt, Germany 
Sodium sulfite (Na2SO3, MW = 126.04) Merck KGaA, Darmstadt, Germany 
Sodiumchloride (NaCl, MW = 58.44) Merck KGaA, Darmstadt, Germany 
Sodiumhydrogencarbonat (NaHCO3, MW = 84.01) Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Sodiumhydroxid (NaOH, MW = 40.0) Merck KGaA, Darmstadt, Germany 
Sodiumpyruvate (CH3COCOONa, MW = 110.04) Gibco-BRL, Karlsruhe, Germany 
SssI methylase New England Biolabs, Ipswich, USA 
Sulfolane (C4H8O2S, MW = 120.17) Merck KGaA, Darmstadt, Germany 
Trishydroxymethylaminomethane, Tris (NH2C(CH2OH)3, 
MW = 121.14) 
Carl Roth GmbH & Co., Karlsruhe, 
Germany 
Triton-X-100 (t-Oct-C6H4-(OCH2CH2)xOH, x= 9-10) Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Water, sterile, filtered 0,2 µm, DEPC treated Fluka GmbH, Buchs, Germany 
6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 
(C14H18O4, MW = 250.29) 
Fluka GmbH, Buchs, Germany 
7.1.3. Cytokines and antibodies 
Antibodies and Cytokines Supplier 
antiCD8 FITC conjugated PharMingen via Becton Dickinson, 
Heidelberg, Germany 
antiCD4 FITC conjugated PharMingen via Becton Dickinson, 
Heidelberg, Germany 
antiCD14 FITC conjugated BD Biosciences, San Jose, USA 
antiCD19 FITC conjugated BD Biosciences, San Jose, USA 
antiIFN-   PerCP Cy5.5 conjugated BD Biosciences, San Jose, USA 
antiIL-10  APC conjugated BD Biosciences, San Jose, USA 
anti H3K4me3 Abcam, Cambridge, UK 
anti H3AcK9/14 Abcam, Cambridge, UK 
BD Tritest (antiCD4/CD8/CD3 conjugated with FITC, PE, and 
PerCP respectively) 
BD Biosciences, San Jose, USA 
mouse IgG Caltag, Burlingame, USA 
anti CD80 PE conjugated BD Biosciences, San Jose, USA 
anti CD83 PE conjugated BD Biosciences, San Jose, USA 
anti CD86 PE conjugated BD Biosciences, San Jose, USA 
anti-CD28 Upstate Biotechnology, Charlottesville, 
VA, USA 
anti-CD3 Upstate Biotechnology, Charlottesville, 
VA, USA 
anti-IL4 Upstate Biotechnology, Charlottesville, 
VA, USA 
rIL-12  Upstate Biotechnology, Charlottesville, 
VA, USA 
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7.1.4. Kits 
Kit Supplier 
BigDye Terminator V3.1 Applied Biosystems, Foster City, USA 
CD14 MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD19 MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD27 MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD4 MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD45RA MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD45RO MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD8 MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
ExoSAP IT USB Corporation, Cleveland, USA 
FASTStart SYBR Green Master Mix Roche Diagnostics, Penzberg, 
Germany 
GenomiPhi® DNA Amplification Kit Amersham Biosciences, Piscataway, 
NJ, USA 
human Th1/Th2 cytokine CBA Kit  Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Human Th1/Th2 Cytokine Cytometric Bead Array Kit BD Biosciences, San Jose, USA 
IFN-   capture assays Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Omniscript Reverse Transcription Kit  Qiagen, Hilden, Germany 
Plasmid Mini Kit Qiagen, Hilden, Germany 
Protein A microbeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
QIAamp DNA Mini Kit Qiagen, Hilden, Germany 
RNeasy Kit  Qiagen, Hilden, Germany 
SYBR Green PCR master mix Applied Biosystems, Foster City, USA 
TOPO TA Cloning Invitrogen, Carlsbad, USA 
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7.1.5. Instruments and devices 
Device Supplier 
ABI Prism 7900HT Applied Biosystems, Foster City, USA 
Balance BL 600 Sartorius AG, Göttingen, Germany 
Centrifuge MiniSpin Eppendorf-Nethler-Hinz GmbH, 
Cologne, Germany 
DNA Engine Tetrad® thermocycler  BioRad, Hercules, USA 
DyeEx™ 96  Qiagen, Hilden, Germany 
Eppendorf UV spectrophotometer Eppendorf AG, Hamburg, Gemany 
FACScalibur BD Biosciences, San Jose, USA 
Ficoll - Hypaque Sigma-Aldrich, St. Louis, Missouri, US 
Gelelectrophoresis chambers Biozym Diagnostik GmbH, Oldendorf, 
Germany 
LightCycler instrument 2.0 Roche Diagnostics, Mannheim, 
Germany 
Microcon Centrifugal Filter Units YM30 Millipore, Billerica USA 
NanoDrop® ND-1000 spectrophotometer Nanodrop Technologies, Wilmington, 
USA  
NucleoSpin Extract II Macherey-Nagel, Düren, Germany 
Pipets Eppendorf-Nethler-Hinz GmbH, 
Cologne, Germany 
Plate centrifuge Eppendorf 5810 R and 5417 R Eppendorf-Nethler-Hinz GmbH, 
Cologne, Germany 
Sonicator Bandelin, Berlin, Germany 
Thermomixer 5355 Comfort Eppendorf-Nethler-Hinz GmbH, 
Cologne, Germany 
  columns Miltenyi Biotec, Bergisch Gladbach, 
Germany 
3730 DNA Analyser Applied Biosystems, Foster City, USA 
96 well microtiter plates (PCR and sequencing) ABgene, Epsom, UK 
 
7.1.6. Software 
Software Supplier 
ABI KB basecaller Applied Biosystems, Foster City, USA 
CELLQuest™ BD Biosciences, San Jose, USA 
FACSDiva BD Biosciences, San Jose, USA 
ESME Lewin, J et al., Bioinformatics, 2004 
ABI SDS 2.2 Applied Biosystems, Foster City, USA 
Q-gene Muller, P.Y. et al., Biotechniques, 2002 
http://www.gene-
quantification.de/download.html#qgene 
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7.3. mRNA primer assays 
Gene 
Primer 
orientation Primer sequence 
GAPDH S GAAATCCCATCACCATCTTCC 
 A ATGAGTCCTTCCACGATACC 
MAF S GGACGCGTACAAGGAGAAAT 
 A GCTTCCAAAATGTGGCGTAT 
EOMES S CGCCACCAAACTGAGATGAT 
 A CAGCACCACCTCTACGAACA 
ETV5 S TGCAGATGCCAAAGATGATG 
 A GATGGTAACTGGGGCGATTA 
FOG1 S ATGTCCAGGCGGAAACAG 
 A GTGGCCTTTTGCTCCATGT 
GATA3 S TACAGCTCCGGACTCTTCCC 
 A GTTGCCCCACAGTTCACAC 
HLX1 S CCTCCAGCAAAGACCTCAAA 
 A CGGTTAGCAGGGAAGTGAGA 
NOTCH1 S GTCCAACCCATGTCTGAACC 
 A GGCAGACACAGGAGAAGCTC 
SPI1 S GTGCAAAATGGAAGGGTTTC 
 A GGGGTAATACTCGTGCGTTT 
TBX21 S CCACCTGTTGTGGTCCAAGT 
 A ACCACGTCCACAAACATCCT 
TCF7 S TCTGCTCATGCATTACCCAC 
 A GATGTGGGCTGTTGAAATGTT 
Th-POK S GTCTGCCACAAGATCATCCA 
 A TGTGGATCTTCAGCTTGTCG 
IFN-   S GACCAGAGCATCCAAAAGA 
 A CTCTTCGACCTCGAAACAGC 
IL-10 S CCAAGCTGAGAACCAAGACC 
 A AAGGCATTCTTCACCTGCTC 
 
Table 3 Intron spanning primer assays for quantitative real – time PCR 
7.4. Chromatin immunoprecipitation primer assays 
Gene Region Primer 
orientation 
Primer sequence  
IL10 1 S GACATCATCCTGCCCATTCT 
  
A AGGGGCACATGTAAATGACAG 
 2 S TGGTGGGCCAGAAGTTTAAG 
  
A GCCTGATTTGGTGCCATAGT 
 4 S TCTCAGCTCACTGCAAGCTC 
  
A ACACAGTGAAACCCCGTCTC 
 5 S AGGGAGGCCTCTTCATTCAT 
  
A AGCTGTTCTCCCCAGGAAAT 
 
Table 4  Primer assays used for amplification of chromatin crosslinked DNA 
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7.5. Sample details 
7.5.1. Donors included in the T-cell pools 
Donor Age (y) 
Gender  
(m: male, f: female) Pool 
1 36 f 1 
2 45 f 1 
3 54 m 1 
4 41 f 1 
5 40 f 1 
6 24 m 1 
7 59 f 1 
8 28 f 1 
9 20 m 1 
10 44 f 1 
11 49 m 2 
12 59 m 2 
13 41 f 2 
14 68 f 2 
15 53 m 2 
16 52 m 2 
17 38 m 2 
18 28 m 2 
19 33 f 2 
20 26 f 2 
21 23 f 3 
22 51 m 3 
23 49 m 3 
24 35 f 3 
25 35 f 3 
26 34 f 3 
27 67 m 3 
28 38 m 3 
29 28 m 3 
30 39 m 3 
 
Table 5  Age and gender of the healthy PBMC donors. Four different Th-cell subsets were obtained from 
each donor and individual subsets were collected in pools. The right column (pool) shows the 
pool composition. 
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7.5.2. Donor DNA used for bisulfite PCR cloning experiments 
  Analyzed clones 
IL-10- / IFN-γ- 
  
Donor1 age : 54  gender : m 19 
Donor2 age : 68  gender : f 17 
IL-10- / IFN-γ+ 
  
Donor1 age : 44  gender : f 19 
Donor2 age : 59  gender : m 19 
IL-10+ / IFN-γ+ 
  
Donor1 age : 53  gender : m 15 
Donor2 age : 67  gender : m 15 
IL-10+ / IFN-γ- 
  
Donor1 age : 44  gender : f 20 
Donor2 age : 23  gender : f 14 
 
Table 6  Age and gender of the individuals selected for clone sequencing. The number of clones per 
individual and cell type is given in the right column. 
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7.5.3. Lymph node tumor and healthy tissue samples 
Sample  
Main 
diagnosis Anatomical origin 
Amount 
of 
tumor 
cells in 
smear 
Pathological 
Staging 
Lymphoma 
(WHO) 
Age at 
extraction Gender 
1 DLBCL Lymphoid tissue / Lymph node 90 I 56 M 
2 DLBCL Lymphoid tissue / Lymph node 90 I 62 M 
3 DLBCL Lymphoid tissue / Lymph node 90 I 69 M 
4 DLBCL Lymphoid tissue / Lymph node 40 IE 74 F 
5 DLBCL Lymphoid tissue / Lymph node 90 I 75 F 
6 DLBCL Lymphoid tissue / Lymph node 90 I 74 M 
7 DLBCL Lymphoid tissue / Lymph node 85 I 75 M 
8 DLBCL Lymphoid tissue / Lymph node 80 IE 65 M 
9 DLBCL Lymphoid tissue / Lymph node 80 IV 72 M 
10 DLBCL Lymphoid Tissue/ Groin 95 I 69 M 
11 DLBCL Lymph Node 90 I 75 F 
12 DLBCL Lymph Node 90 IIE 72 M 
13 DLBCL Lymph Node 90 I 62 M 
14 DLBCL Lymphoid tissue / Spleen 90 IV 61 M 
15 DLBCL Lymph Node 90 I 61 M 
16 DLBCL Lymph Node 90 I 65 M 
17 DLBCL Lymphoid tissue / Spleen 90 IV 55 M 
18 DLBCL Lymph Node 90 I 56 M 
19 DLBCL Lymphoid Tissue / Abdominal cavity 90 IIE 74 F 
20 DLBCL Testis / Brain 75 IV 66 M 
1 T-cell NHL Lymph Node 100 Not Reported 74 F 
2 T-cell NHL Lymph Node 100 Not Reported 56 M 
3 T-cell NHL Lymph Node 100 Not Reported 35 M 
4 T-cell NHL Lymph Node 95 Not Reported 62 M 
5 T-cell NHL Lymph Node 90 Not Reported 58 M 
6 T-cell NHL Lymph Node 85 Not Reported 68 M 
7 T-cell NHL Lymph Node 90 Not Reported 75 M 
8 T-cell NHL Lymph Node 90 Not Reported 69 M 
9 T-cell NHL Lymph Node 90 Not Reported 60 F 
10 T-cell NHL Lymph Node 90 Not Reported 52 F 
11 T-cell NHL Lymph Node 90 Not Reported 52 F 
12 T-cell NHL Lymph Node 85 Not Reported 73 M 
13 T-cell NHL Lymph Node 85 Not Reported 75 M 
14 T-cell NHL Lymph Node 100 Not Reported 89 M 
1 normal Lymph node NA NA 50 M 
2 normal Lymph node NA NA 50 M 
3 normal Lymph Node NA NA 63 F 
4 normal Lymph Node NA NA 74 F 
5 normal Lymph Node NA NA 75 M 
6 normal Lymph Node NA NA 76 M 
7 normal Lymph Node NA NA 74 F 
8 normal Lymph Node NA NA 75 M 
9 normal Lymph Node NA NA 73 F 
10 normal Para-aortal lymph node NA NA 68 F 
11 normal lymph node, Inguinal  NA NA 89 M 
12 normal lymph node, Inguinal  NA NA 75 F 
13 normal lymph node, Inguinal  NA NA 65 M 
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14 normal lymph node, Inguinal  NA NA 72 M 
15 normal Normal lymph node NA NA NA F 
16 normal Normal lymph node NA NA NA M 
17 normal Normal lymph node NA NA NA M 
18 normal lymph node, Inguinal  NA NA 67 M 
 
Table 7  Lymph node biopsy samples used for methylation measurement of hematopoietic transcription 
factors. In the second column, the main diagnosis of the patient is given (DLBCL : diffuse large 
B-cell Non Hodgkin Lymphoma, T-cell NHL: T-cell Non Hodgkin Lymphoma).
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7.6. Abbreviation list 
aIL4 Anti IL4 antibody 
allo DC Allogeneic dendritic cell 
APC Allophycocyanin 
B-cell NHL B-cell Non Hodgkin lymphoma 
bp Base pairs 
BSA Bovine serum albumine 
°C Celsius degree 
CD4 Cluster of differentiation, 4 (surface antigen of helper T -lymphocytes) 
CD45RA Cluster of differentiation, 45, RA isoform, (surface antigen, naive CD4+ T-
lymphocytes) 
CD45RO Cluster of differentiation, 45, RO isoform, (surface antigen, memory CD4+ T-
lymphocytes) 
CD8 Cluster of differentiation, 8 (surface antigen of cytotoxic T -lymphocytes) 
CD8 Cluster of differentiation, 8 (surface antigen, T -lymphocytes) 
CGI CpG island 
ChIP Chromatin Immunoprecipitation 
c-MAF c-maf musculoaponeurotic fibrosarcoma oncogene homolog 
CNS Conserved non coding sequence 
CpG 5'-CG-3'-Dinucleotide 
DC Dendritic cell 
ddNTPs Di-deoxy-nucleotide triphosphate 
DEPC Diethylpyrocarbonate 
DLBCL Diffuse large B-cell lymphoma 
DMEM Dulbecco's Modified Eagle Medium 
dNTPs Deoxy-nucleotide triphosphate 
dsDNA Double stranded DNA 
EDTA Ethylenediaminetetraacetic acid 
EOMES Eomesodermin 
ETV5 Ets variant gene 5 
FACS Flourescence activated cell sorting 
FITC Fluorescein isothiocyanat 
FL Fluorescence 
FOG1 Friend of GATA1 
GAPDH Glycerol aldehyd-3-phosphate dehydrogenase 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GATA3 GATA binding protein 3 
GM-CSF Granulocyte Macrophage Colony Stimulating Factor 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLX1 H2.0-like homeo box 1 
I Ionomycin 
IFN-   Interferon gamma gene 
IFN-   Interferon gamma 
IL10 Interleukin 10 gene 
IL-10 Interleukin 10 
IL13 Interleukin 13 gene 
IL-13 Interleukin 13 
IL2 Interleukin 2 gene 
IL-2 Interleukin 2 
IL4 Interleukin 4 gene 
IL-4 Interleukin 4 
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IL5 Interleukin 5 gene 
IL-5 Interleukin 5 
 
 Wavelength 
LOI Loss of imprinting 
LPS Lipopolysacharide 
MACS Magnetic activated cell sorting 
mg Milligramm 
MHC Multihistocompatibility complex 
µl Microliter 
mm Milimeters 
ng Nanogramm 
nm Nanometers 
NOTCH1 Notch homolog 1, translocation-associated 
P/I Phorbol 12-myristate 13-acetate / ionomycin 
PBMC Peripheral blood mononucleated cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PMA Phorbol 12-myristate 13-acetate 
RA Rheumatoid Arthritis 
rIL-12 Recombinant IL-12 
rIL-4 Recombinant IL-4 
RPMI Roswell Park Memorial Institute 
SAM S-adenosylmethionine 
SPI1 Spleen focus forming virus (SFFV) proviral integration oncogene 
ssDNA Single stranded DNA 
TBX21 T-box protein 21 
T-cell NHL T-cell Non Hodgkin lymphoma 
TCF7 Transcription factor 7 (T-cell specific) 
TCR T - cell receptor 
TE Tris - EDTA buffer 
Th helper T-cells 
Th-POK T-helper-inducing POZ/Krüppel-like factor 
Treg regulatory T-cells 
TSS Transcription start site 
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7.7. Eidesstattliche Erklärung 
 
Hiermit versichere ich, dass die vorliegende Arbeit eigenständig und ohne jede unerlaubte Hilfe 
angefertigt wurde. Alle von mir verwendeten Hilfsmittel und Quellen sind als solche gekennzeichnet. 
